



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A01K 67/00, C07H 21/04, C07K 1/00,</b> <b>C12N 5/00, 15/00, G01N 33/00, 33/53,</b> <b>33/567</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 00/35274</b> <b>(43) International Publication Date:</b> 22 June 2000 (22.06.00)
<b>(21) International Application Number:</b> PCT/US99/30221 <b>(22) International Filing Date:</b> 17 December 1999 (17.12.99)  <b>(30) Priority Data:</b> 60/112,605 17 December 1998 (17.12.98) US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 60/112,605 (CIP) Filed on 17 December 1998 (17.12.98)  <b>(71) Applicant (for all designated States except US):</b> THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE [US/US]; 720 Rutland Avenue, Baltimore, MA 21205 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> REED, Randall, R. [US/US]; 111 Overhill Road, Baltimore, MD 21210 (US). KRAUTWURST, Dietmar [DE/DE]; Arthur-Scheunert-Allee 114-116, D-14558 Bergholz Rehbrücke (DE). YAU, King, Wai [US/US]; 1502 Pinnacle Road, Baltimore, MD 21286 (US).	<b>(74) Agents:</b> WETHERELL, John, R. et al.; Fish & Richardson P.C., Suite 1400, 4225 Executive Square, La Jolla, CA 92037 (US).  <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
<b>(54) Title:</b> OLFACTORY RECEPTOR EXPRESSION LIBRARIES AND METHODS OF MAKING AND USING THEM  <b>(57) Abstract</b> <p>This invention provides novel libraries of olfactory receptor odorant/ligand-binding domains and methods of making and using them. The invention also provides libraries of vectors and cells comprising these nucleic acid constructs. The compositions and methods of the invention are used to identify novel ligand-binding domains for olfactory neuron odorant receptors and their ligands. Thus, the compositions and methods of the invention can be used to generate novel odorants, to screen for toxic odorants, or to manipulate an animal's olfactory response.</p>		

BEST AVAILABLE COPY

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## **OLFACTORY RECEPTOR EXPRESSION LIBRARIES AND METHODS OF MAKING AND USING THEM**

### **FIELD OF THE INVENTION**

5 This invention generally pertains to the fields of cell biology and medicine. In particular, this invention provides novel libraries of nucleic acids encoding odorant/ligand-binding domains. Also provided are libraries of hybrid 7-transmembrane olfactory receptors comprising these odorant ligand-binding domains. The compositions and methods of the invention can be used to identify novel ligand-binding domains for olfactory neuron odorant receptors and their ligands. Thus, the compositions and methods of the invention can be used  
10 to generate novel odorants and to manipulate an animal's olfactory response.

### **BACKGROUND OF THE INVENTION**

A better understanding of the vertebrate olfactory system would provide improved means to manipulate this process and possibly prevent disease or injury. For example, means to manipulate human olfactory neuron odorant receptors from healthy  
15 individuals and from individuals with neuro-psychiatric illnesses would offer systems for testing possible odorant/ligands for therapeutic and toxic effects. However, our ability to detect and discriminate between the thousands of beneficial or toxic odorants is complicated by the fact that odorant receptors belong to a multigene family with at least 500 to 1000 members. Furthermore, each olfactory receptor neuron may express only one, or at most a  
20 few, of these olfactory receptors. Any given olfactory neuron cell can respond to a small, arbitrary set of odorant-ligands. Odorant discrimination for a given neuron may depend on the ligand specificity of the one or few receptors it expresses. Thus, given this systems' complexity, information about odorant/ligand-receptor recognition remains meager.

To analyze odorant/ligand-receptor interactions and their effects on cell  
25 physiology, it is first necessary to identify specific odorant/ligand(s) and the olfactory receptors to which they specifically bind. Such analysis requires isolation and expression of olfactory receptor polypeptides. However, despite the fact that many putative olfactory receptors have been cloned, only limited progress has been made in the functional expression of these receptors because present systems fail to efficiently translocate these 7-

transmembrane proteins to the plasma membrane. This may be because olfactory receptors are a subclass of 7-transmembrane-domain receptors. For example, expression of one rat olfactory receptor in insect cells resulted in only a modest elevation in second messengers when exposed to a mixture of odorants; responses to single compounds were not seen  
5 (Raming (1993) Nature 361:353-356). The present invention addresses these and other needs.

### SUMMARY OF THE INVENTION

The present invention provides novel compositions and methods to generate great numbers, or libraries, of odorant receptor ligand-binding regions. Also provided are  
10 novel chimeric olfactory receptors that incorporate these libraries of odorant binding domains. The present invention also provides novel compositions and methods to efficiently translocate polypeptides to the plasma membrane surface. Another aspect of the invention is based on the surprising discovery of a peptide domain that, when incorporated into a polypeptide, can with great efficiency "chaperone" or translocate the hybrid protein to the  
15 cell plasma membrane. Combining these two aspects of the invention also provides expression vectors and cells that efficiently express these recombinant proteins. Cells and transgenic animals efficiently expressing libraries of hybrid olfactory receptors can be used for screening potential beneficial and toxic odorant molecules.

The invention provides an amplification primer sequence pair for amplifying a  
20 nucleic acid encoding an olfactory receptor ligand-binding region comprising a first primer comprising a sequence 5'-GGGGTCCGGAG(A/G)(C/G)  
(A/G)TA(A/G/T)AT(A/G/P)A(A/G/P)(A/G/P)GG-3' (SEQ ID NO:1) and a second primer comprising a sequence 5'-GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T)  
(C/T)T(A/C/G/T)TT(C/T)(C/T)T-3' (SEQ ID NO:2). When used to amplify olfactory  
25 receptor nucleic acid sequences, it typically amplifies the receptor ligand-binding region comprising olfactory receptor transmembrane (TM) domains II through VII.

The invention also provides a method for generating nucleic acid sequence that encodes a ligand-binding region of an olfactory receptor, the method comprising amplification of a nucleic acid using the primer pair SEQ ID NO:1 and SEQ ID NO:2. In  
30 this method the amplified nucleic acid can be genomic DNA, mRNA or cDNA derived from olfactory neurons or olfactory epithelium. The amplification can be by polymerase chain reaction (PCR), wherein the PCR amplification comprises the following conditions and steps

in the following order: about one cycle at about 94°C for about 2 min; and about 30 cycles of about 45°C to about 65°C for about 1 min, followed by about 72°C for about one min. followed by about 94°C for about 1 min. The PCR amplification protocol can further comprise the following conditions and steps in the following order: about one cycle of about 45°C to about 65°C for about 10 min; and about one cycle of about 72°C for about 10 min.

Also provides is a kit for amplification of olfactory receptor sequences comprising primer pairs that can amplify olfactory receptor transmembrane domain regions II through VII, II through VI, III through VII, or III through VI, e.g., SEQ ID NO:1 and SEQ ID NO:2 to amplify TM II through VII.

The invention also provides a library of olfactory receptor ligand-binding regions consisting essentially of olfactory receptor transmembrane domain regions II through VII, II through VI, III through VII, or III through VI, including partial domains, or a combination of domain sequences. The library of the olfactory receptor ligand-binding regions can be generated by PCR using degenerate primer pairs.

Also provided is a library of chimeric nucleic acid sequences comprising the following domains in 5' to 3' order: a nucleic acid encoding an amino terminal plasma membrane translocation domain; a nucleic acid encoding a first transmembrane domain; and a nucleic acid encoding an olfactory receptor ligand-binding region, wherein the chimeric nucleic acid sequence encodes a 7-transmembrane polypeptide that can transverse a plasma membrane seven times. The amino terminal plasma membrane translocation domain comprises an amino acid sequence as set forth in SEQ ID NO:3 (and encoded by a subsequence of SEQ ID NO:6): 5'-

5' -GGATCCGGGTTTCGCGCCGCCGCGGGCAGCCGCAAGGGCCGAGCCATGAACGGGACCGAGGGC

M N G T E G

CCAACTTCTACGTGCCTTTCTCCAACAAGACGGGCGTGGTGAATTC-3' (SEQ ID NO:6)

P N F Y V P F S N K T G V V (SEQ ID NO:3)

In alternative embodiments, the nucleic acid encoding the first transmembrane domain can be just a polynucleotide sequence encoding SEQ ID NO:3, or, SEQ ID NO:6 (including 45 nucleotides upstream of the initiation codon) or a subsequence thereof.

The first transmembrane receptor of the sequences of the library can be a 7-transmembrane receptor region I domain, or subsequence thereof, e.g., the sequence between the Eco R1 and Pst 1 sites of the M4-chimeric olfactory receptor of the invention (SEQ ID NO:4), as schematically represented in Figure 1A; the full length sequence of the hybrid

receptor has an amino acid sequence as set forth in SEQ ID NO:55, a nucleic acid that can encode this protein is SEQ ID NO:54, described below.

The olfactory receptor ligand-binding regions of the library can comprise olfactory receptor transmembrane domain regions II through VII, II through VI, III through VII, or III through VI, or a combination thereof. These olfactory receptor ligand-binding regions can be generated by amplification, e.g., PCR, using degenerate primer pairs. The library's nucleic acid sequence encoding transmembrane domain regions II through VII can be generated by PCR amplification of nucleic acid using a first primer comprising a sequence 5'-GGGGTCCGGAG(A/G)(C/G)(A/G)TA(A/G/T)AT(A/G/P)A(A/G/P)(A/G/P)GG-3' (SEQ ID NO:1) and a second primer comprising a sequence 5'-GGGGCTGCA GACACC(A/C/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)TT(C/T)(C/T)T-3' (SEQ ID NO:2). The library can be generated from PCR-amplified nucleic acid isolated as or derived from genomic DNA, mRNA or cDNA derived from olfactory neurons or olfactory epithelium.

Exemplary ligand-binding regions comprising transmembrane domains II through VII can be an amino acid sequence encoded by a nucleic acid selected from the group consisting of SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45 and SEQ ID NO:47, or an amino acid sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48.

To generate the nucleic acids of the library, PCR amplification can comprise the following conditions and steps in the following order: about one cycle at about 94°C for about 2 min; about 30 cycles of about 55°C for about 1 min, followed by about 72°C for about one min. followed by about 94°C for about 1 min; about one cycle of about 55°C for about 10 min; and about one cycle of about 72°C for about 10 min.

The library can further comprise a carboxy terminal 7-transmembrane receptor transmembrane region VII domain or subsequence thereof, e.g., the sequence between the Bsp E1 and Xba 1 sites of the M4-chimeric olfactory receptor of the invention (SEQ ID NO:6), as schematically represented in Figure 1A; the full length sequence of the

hybrid receptor has an amino acid sequence as set forth in SEQ ID NO:55, a nucleic acid that can encode this protein is SEQ ID NO:54.

The library of nucleic acid sequences can also comprise the following domains in 5' to 3' order: a nucleic acid encoding an amino terminal plasma membrane translocation domain comprising a sequence as set forth in SEQ ID NO:3, a nucleic acid encoding a transmembrane region I domain comprising a sequence as set forth in SEQ ID NO:4, a nucleic acid sequence generated by polymerase chain reaction (PCR) amplification of mRNA or cDNA derived from olfactory epithelium using a first primer comprising a sequence 5'-GGGGTCCGGAG(A/G)(C/G)T(A/G)A(A/G/T)AT (A/G/P)A(A/G/P)(A/G/P)GG-3' (SEQ ID NO:1) and a second primer comprising a sequence 5'-GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T)C/T)T(A/C/G/T)TT(C/T)C/T)T-3' (SEQ ID NO:2), and a nucleic acid encoding a 7-transmembrane receptor transmembrane region VII domain comprising a sequence as set forth in SEQ ID NO:6.

Also provided are expression vectors (e.g., plasmids, viruses) comprising a nucleic acid sequence derived from the libraries of nucleic acid sequences of the invention. Transformed or isolated infected cells comprising a nucleic acid sequence derived from a library of nucleic acid sequences of the invention or an expression vector of the invention are also provided. Transgenic non-human animals comprising a nucleic acid sequence derived from a library of nucleic acid of the invention or an expression vector of the invention are also provided. In the transgenic animal, the expression vector can be a mammalian expression vector that can be expressed in olfactory epithelium or olfactory neurons.

The invention also provides a library of recombinant polypeptides translated or derived from the library of nucleic acids of the invention. Also provided are polypeptides isolated or derived from the library of polypeptides of the invention.

Also provided are methods of determining whether a test compound specifically binds to a mammalian olfactory receptor comprising the following steps: expressing a nucleic acid derived from a nucleic acid library of the invention under conditions permissive for translation of the nucleic acid to a receptor polypeptide; contacting the translated polypeptide with the test compound; and determining whether the test compound specifically binds to the polypeptide.

Also provided are methods of determining whether a test compound specifically binds to a mammalian olfactory transmembrane receptor comprising the

following steps: contacting a cell stably or transiently transfected with a nucleic acid derived from a nucleic acid library of the invention; culturing the cell under conditions permissive for translation of the nucleic acid to a receptor polypeptide with the test compound; and determining whether the test compound specifically binds to the receptor polypeptide. In this method, the receptor polypeptide can be expressed as a transmembrane receptor with a ligand-binding site on the cell's plasma membrane outer surface. The specific binding of the test compound to the polypeptide can be determined by measuring a change in the physiologic activity of the cell, wherein a change in the cell's activity measured in the presence of the test compound compared to the cell's activity in the absence of the test compound provides a determination that the test compound specifically binds to the polypeptide. The measured cell activity can be a change in the calcium ion ( $\text{Ca}^{2+}$ ) or cAMP concentration in the cell, which can be measured by loading the cell with a calcium ion-sensitive fluorescent dye before contacting the cell with the test compound. In this method any cell can be used, e.g., a human cell or a *Xenopus* oocyte.

Also provided are methods of determining whether a test compound specifically binds to a mammalian olfactory transmembrane receptor polypeptide *in vivo* comprising the following steps: contacting a non-human animal stably or transiently infected with a nucleic acid derived from the library of the invention or an expression vector of the invention with the test compound; and determining whether the animal reacts to the test compound by specifically binding to the receptor polypeptide, wherein the specific binding of the test compound to the polypeptide is determined by measuring a change in a physiologic activity of the animal, wherein a change in a receptor-encoding vector-infected animal's activity measured in the presence of the test compound compared to a bare vector-infected animal's activity in the presence of the test compound provides a determination that the test compound specifically binds to the mammalian olfactory transmembrane receptor polypeptide. In this method, the measured physiologic activity can be measured by an electroolfactogram. The vector can be a recombinant virus, e.g., an adenovirus expression vector.

The invention also provides a method of determining whether a test compound is neurotoxic to an olfactory neuron expressing an olfactory transmembrane receptor polypeptide comprising the following steps: contacting an olfactory neuron cell stably or transiently infected with a nucleic acid derived from a library as set forth in claim 8



or claim 10 or an expression vector as set forth in claim 23 with the test compound; and measuring the physiologic activity of the cell, wherein a change in the cell's activity measured in the presence of the test compound compared to the cell's activity in the absence of the test compound provides a determination that the test compound is toxic. In this method toxicity can be indicated by abnormal calcium ion, cAMP or plasma membrane homeostasis.

Also provided are peptide domains for the efficient translocation of a newly translated protein to a plasma membrane comprising an amino acid sequence as set forth in SEQ ID NO:3 or an amino acid sequence having conservative amino acid residue substitutions based on SEQ ID NO:3. Translocation domains within the scope of the invention include amino acid sequences functionally equivalent to the exemplary translocation domain of the invention SEQ ID NO:3. The peptide translocation domain can be at least about 20 amino acids in length, at least about 30 amino acids in length or at least about 40 amino acids in length. The peptide translocation domain can have a sequence as set forth in SEQ ID NO:3, or, be encoded by a nucleic acid comprising a sequence as set forth in SEQ ID NO:6. The newly translated protein can be a transmembrane protein, e.g., a 7-transmembrane protein receptor, e.g., an olfactory receptor.

The invention also provides a hybrid (chimeric) polypeptide comprising an amino terminal amino acid sequence comprising a peptide translocation domain of the invention and a second polypeptide sequence, wherein the second polypeptide sequence is not a rhodopsin polypeptide sequence. The second polypeptide sequence can be a transmembrane protein, e.g., a 7-transmembrane protein receptor, e.g., an olfactory receptor. Also provided are isolated or recombinant nucleic acid sequences encoding these hybrid polypeptides. For example, an exemplary chimeric polypeptide of the invention and a polynucleotide that encodes this hybrid, described in the Example below and schematically represented in Figure 1A as the insert from BamHI to XbaI, have the amino acid (SEQ ID NO:55) and nucleic acid (SEQ ID NO:54) sequence, respectively (restriction enzyme sites are also indicated):

BamHI  
GGATCCGGGTTTCGCGCCGCCGGCGGGCAGCCGCAAGGGCCGCAGCCATGAACGGGACCGAGGGC  
M N G T E G  
EcoRI  
CCAAACTTCTACGTGCCTTTCTCCAACAAGACGGGCGTGGTGAATTCCCCGGTCAGAACTACA  
P N F Y V P F S N K T G V V E F P G Q N Y S

GCACCATATCAGAATTTATCCTCTTTGGTTTCTCAGCCTTCCCACACCAGATGCTCCCTGCTCT  
S T I S E F I L F G F S A F P H Q M L P A L

5 GTTCCTGCTCTACTTGCTGATGTATTTGTTCACTCTTCTGGGGAACCTGGTCATCATGGCTGCT  
F L L Y L L M Y L F T L L G N L V I M A A

PstI BspEI  
ATCTGGACAGAACATAGACTGCAGACACCCATCCGAAAGGAGCTGAAGAATGCTATAATTAAA  
I W T E H R L Q S G K E L K N A I I K

10 XbaI  
AGCTTCCACAGGAATGTCTGTCAACAAAGTATCTAAGTGTCAAGTTCTGTCTAGA (SEQ ID NO:54)  
S F H R N V C Q Q S I STOP (SEQ ID NO:55)

A further understanding of the nature and advantages of the present invention  
15 is realized by reference to the remaining portions of the specification, the figures and claims.

All publications, GenBank deposited sequences, ATCC deposits, patents and  
patent applications cited herein are hereby expressly incorporated by reference for all  
purposes.

## BRIEF DESCRIPTION OF THE DRAWINGS

20 Figure 1A shows a schematic of a mammalian expression construct of the  
invention comprising a translocation domain of the invention and an odorant/ligand-binding  
domain generated by degenerate PCR primers, as described in detail in Example 1, below.

## DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel compositions and methods to efficiently  
25 translocate newly translated polypeptides to the plasma membrane surface. This aspect of  
the invention is based on the surprising discovery of peptide domains (e.g., SEQ ID NO:3)  
that, when incorporated into the amino terminus of a polypeptide coding sequence, can with  
great efficiency "chaperone" or "translocate" the hybrid ("fusion") protein to the cell plasma  
membrane. This "translocation domain" was initially derived from the amino terminus of the  
30 human rhodopsin receptor polypeptide, a 7-transmembrane receptor. Thus, the translocation  
domain of the invention is particularly efficient in translocating 7-transmembrane fusion  
proteins to the plasma membrane. For example, the mouse olfactory receptor M4 (see, e.g.,  
Qasba (1998) J. Neurosci. 18:227-236) expressed in a mammalian cell line is inefficiently  
translocated to the cell. In contrast, when a translocating domain of the invention (SEQ ID  
35 NO:3) was spliced to the amino terminus of the M4 olfactory receptor polypeptide, cell  
surface expression of the newly translated protein increased from undetectable levels to 10%

or more of the total expressed protein (as determined by confocal microscopic imaging with antibodies that recognize the carboxyl terminus of the M4 receptor). Furthermore, subsequent functional expression studies demonstrated that no responses could be observed upon addition of extracellular ligand unless the translocation domain of the invention (SEQ ID NO:3) was included to effect surface localization.

The invention also provides novel means to generate libraries of odorant/ligand-binding regions of olfactory receptor proteins. Great numbers of these ligand-regions can be generated by amplification (e.g., by polymerase chain reaction (PCR)) of nucleic acid from olfactory neurons and epithelium using degenerate primer pairs. The primer pairs selectively amplify the odorant/ligand-binding regions of olfactory receptor proteins. The odorant/ligand-binding regions can comprise transmembrane domain II through VII, III through VII, III through VI, II through VI, or combinations or variation thereof, of the 7-transmembrane olfactory receptor (see below for detailed discussion). Thus, amplification of, e.g., genomic DNA, or message or cDNA from olfactory neurons, using the degenerate primers of the invention can generate great numbers, or "libraries," of odorant/ligand-binding region encoding nucleic acid.

The odorant/ligand-binding region-amplifying degenerate primers of the invention are at least about 17 base pair residues in length. Amplification conditions can vary; however, lower temperature conditions (e.g., below about 55°C, usually not lower than about 45°C) will generate libraries of greater complexity and higher temperatures (e.g., over about 55°C) will generate libraries of less complexity:

For screening and identification of odorant/ligands that specifically bind to the domains encoded by the nucleic acid "libraries" of the invention, the amplified sequences can be recombinantly spliced into a "framework" polypeptide that is expressed on the cell surface. If functional studies (including, e.g., cell signaling responses, e.g., calcium transients) are desired, 7-membrane polypeptide coding sequences are used as "donor" regions. In this scheme, the "donor" 7-membrane polypeptide provides the coding sequence needed to complement the insert, i.e., a nucleic acid from an odorant/ligand-binding region library of the invention. For example, if the amplified odorant/ligand-binding region is equivalent to transmembrane domain II through VII, the "donor" provides transmembrane domain I; if the binding region is transmembrane domain III through VI, the "donor" provides the amino terminal transmembrane domain I and the carboxy terminal domain VII;

and the like. Any 7-membrane polypeptide coding sequence can be used as "donor," including olfactory receptor polypeptide; however, some receptors which depend on long amino-terminal extensions for ligand recognition and binding (e.g., metabotropic glutamate, extracellular calcium sensors, GnRH and FSH peptide hormone receptors) may not produce functional receptors using this method.

These constructs can be cloned into expression systems, e.g., plasmids, vectors, viruses and the like. Any system can be used, from a minimal transcription unit (e.g., an expression cassette) to a recombinant virus capable of infecting an animal (e.g., an engineered adenovirus). These vectors can be used for functional expression assays *in vitro* or *in vivo* to screen large numbers of putative odorant/ligand molecules or to test for potential odorant toxicity.

The efficiency of the odorant-receptor screening systems of the invention are greatly increased by generating odorant receptor fusion proteins that can efficiently translocate to the plasma membrane. These hybrid receptors comprise the polypeptide translocating domains and the libraries of odorant/ligand-binding regions of the invention. With this scheme the invention provides an efficient means to generate and efficiently express thousands of olfactory receptor binding domains in functional cell and animal assays for the rapid screening of potential beneficial and toxic odorant/ligands.

Both *in vitro* and *in vivo* systems can be constructed and used in the methods of the invention. *In vitro* screening can include, e.g., liposome or lipid or planar membrane models. *In vivo* screening systems can include, e.g., use of human cells, e.g., olfactory neuron cell lines, or infection of animals (e.g., with virus with sequence encoding chimeric receptor) and transgenic animals that express the constructs of the invention. Adenovirus gene transfer vectors are particularly efficient for the transfer of nucleic acids encoding the hybrid olfactory receptor proteins of the invention to nasal/respiratory epithelium.

When human olfactory receptor nucleic acid is amplified, the *in vitro* models, cultured cells, and infected and transgenic animals can be used for screening large numbers of molecules for their potential as human odorants. The effect of an odorant on neuronal cell physiology can be also assessed. For example, the screening systems of the invention can be used to test whether an odorant/ligand may be potentially toxic (or beneficial) in humans. Any cell physiologic activity can be measured, e.g., cell death, cell growth, intracellular calcium ion changes, second messengers (e.g., G protein activation, cAMP increases), and

the like. The effect of odorant/ligands on apoptotic mechanisms, neuronal growth characteristics (such as neuron population doubling time and length of processes), ion exchange and other measurable parameters can also be used to analyze their potential potency and toxicity.

5                   DEFINITIONS:

                  The term "amplifying" and "amplification" as used herein incorporates its common usage and refers to the use of any suitable amplification methodology for generating or detecting recombinant or naturally expressed nucleic acid, as described in detail, below. For example, the invention provides methods and reagents (*e.g.*, specific degenerate  
10                   oligonucleotide primer pairs) for amplifying (*e.g.*, by polymerase chain reaction, PCR) naturally expressed (*e.g.*, genomic or mRNA) or recombinant (*e.g.*, cDNA) nucleic acids of the invention (*e.g.*, odorant/ligand binding sequences of the invention) *in vivo* or *in vitro*.

                  The term "7-transmembrane receptor" means a polypeptide belonging to a superfamily of transmembrane proteins that have seven domains that span the plasma  
15                   membrane seven times (thus, the seven domains are called "transmembrane" or "TM" domains TM I to TM VII). Olfactory receptors belong to this family. 7-transmembrane receptor polypeptides have similar and characteristic primary, secondary and tertiary structures, as discussed in detail below.

                  The term "expression vector" refers to any recombinant expression system for  
20                   the purpose of expressing a nucleic acid sequence of the invention *in vitro* or *in vivo*, constitutively or inducibly, in any cell, including prokaryotic, yeast, fungal, plant, insect or mammalian cell. The term includes linear or circular expression systems. The term includes expression systems that remain episomal or integrate into the host cell genome. The expression systems can have the ability to self-replicate or not, *i.e.*, drive only transient  
25                   expression in a cell. The term includes recombinant expression "cassettes" which contain only the minimum elements needed for transcription of the recombinant nucleic acid.

                  As used herein, "isolated," when referring to a molecule or composition, such as, *e.g.*, an isolated infected cell comprising a nucleic acid sequence derived from a library of the invention, means that the molecule or composition (including, *e.g.*, a cell) is separated  
30                   from at least one other compound, such as a protein, DNA, RNA, or other contaminants with which it is associated *in vivo* or in its naturally occurring state. Thus, a nucleic acid sequence is considered isolated when it has been isolated from any other component with which it is

naturally associated. An isolated composition can, however, also be substantially pure. An isolated composition can be in a homogeneous state. It can be in a dry or an aqueous solution. Purity and homogeneity can be determined, *e.g.*, using any analytical chemistry technique, as described herein.

5           The term "library" means a preparation that is a mixture different nucleic acid or polypeptide molecules, such as the library of recombinantly generated olfactory receptor ligand binding domains generated by amplification of nucleic acid with degenerate primer pairs, *e.g.*, SEQ ID NO:1 and SEQ ID NO:2, or an isolated collection of vectors that incorporate the amplified odorant/ligand binding domains of the invention, or a mixture of  
10       cells each randomly transfected with at least one vector of the invention.

          The term "nucleic acid" or "nucleic acid sequence" refers to a deoxy-ribonucleotide or ribonucleotide oligonucleotide in either single- or double-stranded form. The term encompasses nucleic acids, *i.e.*, oligonucleotides, containing known analogues of natural nucleotides. The term also encompasses nucleic-acid-like structures with synthetic  
15       backbones, see *e.g.*, *Oligonucleotides and Analogues, a Practical Approach*, ed. F. Eckstein, Oxford Univ. Press (1991); *Antisense Strategies*, Annals of the N.Y. Academy of Sciences, Vol. 600, Eds. Baserga et al. (NYAS 1992); Milligan (1993) *J. Med. Chem.* 36:1923-1937; *Antisense Research and Applications* (1993, CRC Press), WO 97/03211; WO 96/39154; Mata (1997) *Toxicol. Appl. Pharmacol.* 144:189-197; Strauss-Soukup (1997) *Biochemistry*  
20       36:8692-8698; Samstag (1996) *Antisense Nucleic Acid Drug Dev* 6:153-156.

          The term "P" in the sequence is 5'-Dimethoxytrityl-N-benzoyl-2'-deoxy-Cytidine,3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite, or equivalent thereof. "P" can be purchased by, *e.g.*, Glen Research, Sterling, VA, described as "dC-CE Phosphoramidite" catalog number 10-1010-xx.

25           The term "olfactory receptor ligand-binding region" or "olfactory receptor ligand-binding domain" means a sequence derived from an olfactory receptor that substantially incorporates transmembrane domains II to VII (TM II to VII). The domain may be capable of binding a ligand.

          The term "plasma membrane translocation domain" or simply "translocation domain" means a polypeptide domain that is functionally equivalent to the exemplary translocation domain of the invention (SEQ ID NO:3). Exemplary amino terminal plasma membrane translocation domain SEQ ID NO:3 was initially derived from the rhodopsin  
30

receptor amino terminus. A protein (e.g., an olfactory receptor polypeptide) comprising SEQ ID NO:3 as an amino terminal translocating domain will be transported to the plasma membrane more efficiently than without the domain (e.g., as discussed above, M4 receptor expression increased from undetectable levels to at least 10% of the total expressed protein).  
5 "Functional equivalency" means the domain's ability and efficiency in translocating newly translated proteins to the plasma membrane as efficiently as exemplary SEQ ID NO:3 under similar conditions; relatively efficiencies can be measured (in quantitative terms) and compared, as described herein. Domains falling within the scope of the invention can be determined by routine screening for their efficiency in translocating newly synthesized  
10 polypeptides to the plasma membrane in a cell (mammalian, *Xenopus*, and the like) with the same efficiency as the twenty amino acid long translocation domain SEQ ID NO:3, as described in detail below.

The "translocation domain," odorant/ligand binding domains, and chimeric receptors compositions of the invention also include "analogs," or "conservative variants"  
15 and "mimetics" ("peptidomimetics") with structures and activity that substantially correspond to the exemplary sequences, such as the SEQ ID NO:3 translocation domain. Thus, the terms "conservative variant" or "analog" or "mimetic" refer to a polypeptide which has a modified amino acid sequence, such that the change(s) do not substantially alter the polypeptide's (the conservative variant's) structure and/or activity, as defined herein. These  
20 include conservatively modified variations of an amino acid sequence, i.e., amino acid substitutions, additions or deletions of those residues that are not critical for protein activity, or substitution of amino acids with residues having similar properties (e.g., acidic, basic, positively or negatively charged, polar or non-polar, etc.) such that the substitutions of even critical amino acids does not substantially alter structure and/or activity. Conservative  
25 substitution tables providing functionally similar amino acids are well known in the art. For example, one exemplary guideline to select conservative substitutions includes (original residue followed by exemplary substitution): ala/gly or ser; arg/ lys; asn/ gln or his; asp/glu; cys/ser; gln/asn; gly/asp; gly/ala or pro; his/asn or gln; ile/leu or val; leu/ile or val; lys/arg or gln or glu; met/leu or tyr or ile; phe/met or leu or tyr; ser/thr; thr/ser; trp/tyr; tyr/trp or phe;  
30 val/ile or leu. An alternative exemplary guideline uses the following six groups, each containing amino acids that are conservative substitutions for one another: 1) Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamic acid (E); 3) Asparagine (N),

Glutamine (Q); 4) Arginine (R), Lysine (K); 5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W); (see also, e.g., Creighton (1984) *Proteins*, W.H. Freeman and Company; Schulz and Schirmer (1979) *Principles of Protein Structure*, Springer-Verlag). One of skill in the art will appreciate that the above-identified substitutions are not the only possible conservative substitutions. For example, for some purposes, one may regard all charged amino acids as conservative substitutions for each other whether they are positive or negative. In addition, individual substitutions, deletions or additions that alter, add or delete a single amino acid or a small percentage of amino acids in an encoded sequence can also be considered "conservatively modified variations."

The terms "mimetic" and "peptidomimetic" refer to a synthetic chemical compound that has substantially the same structural and/or functional characteristics of the polypeptides, e.g., translocation domains or odorant-ligand binding domains or chimeric receptors of the invention. The mimetic can be either entirely composed of synthetic, non-natural analogues of amino acids, or, is a chimeric molecule of partly natural peptide amino acids and partly non-natural analogs of amino acids. The mimetic can also incorporate any amount of natural amino acid conservative substitutions as long as such substitutions also do not substantially alter the mimetic's structure and/or activity. As with polypeptides of the invention which are conservative variants, routine experimentation will determine whether a mimetic is within the scope of the invention, i.e., that its structure and/or function is not substantially altered. Polypeptide mimetic compositions can contain any combination of non-natural structural components, which are typically from three structural groups: a) residue linkage groups other than the natural amide bond ("peptide bond") linkages; b) non-natural residues in place of naturally occurring amino acid residues; or c) residues which induce secondary structural mimicry, i.e., to induce or stabilize a secondary structure, e.g., a beta turn, gamma turn, beta sheet, alpha helix conformation, and the like. A polypeptide can be characterized as a mimetic when all or some of its residues are joined by chemical means other than natural peptide bonds. Individual peptidomimetic residues can be joined by peptide bonds, other chemical bonds or coupling means, such as, e.g., glutaraldehyde, N-hydroxysuccinimide esters, bifunctional maleimides, N,N'-dicyclohexylcarbodiimide (DCC) or N,N'-diisopropylcarbodiimide (DIC). Linking groups that can be an alternative to the traditional amide bond ("peptide bond") linkages include, e.g., ketomethylene (e.g., -C(=O)-



CH<sub>2</sub>- for -C(=O)-NH-), aminomethylene (CH<sub>2</sub>-NH), ethylene, olefin (CH=CH), ether (CH<sub>2</sub>-O), thioether (CH<sub>2</sub>-S), tetrazole (CN<sub>4</sub>-), thiazole, retroamide, thioamide, or ester (see, e.g., Spatola (1983) in Chemistry and Biochemistry of Amino Acids, Peptides and Proteins, Vol. 7, pp 267-357, "Peptide Backbone Modifications," Marcell Dekker, NY). A polypeptide can also be characterized as a mimetic by containing all or some non-natural residues in place of naturally occurring amino acid residues; non-natural residues are well described in the scientific and patent literature.

As used herein, "recombinant" refers to a polynucleotide synthesized or otherwise manipulated *in vitro* (e.g., "recombinant polynucleotide"), to methods of using recombinant polynucleotides to produce gene products in cells or other biological systems, or to a polypeptide ("recombinant protein") encoded by a recombinant polynucleotide. "Recombinant means" also encompass the ligation of nucleic acids having various coding regions or domains or promoter sequences from different sources into an expression cassette or vector for expression of, e.g., inducible or constitutive expression of a fusion protein comprising a translocation domain of the invention and a nucleic acid sequence amplified using a primer of the invention.

The term "transmembrane domain" means a polypeptide domain that can completely span the plasma membrane. The general secondary and tertiary structure of transmembrane domains, particular the seven transmembrane domains of 7-transmembrane receptors such as olfactory receptors, are well known in the art. Thus, primary structure sequence can be designed or predicted based on known transmembrane domain sequences, as described in detail, below. One such exemplary domain is the 7-transmembrane receptor transmembrane region I domain comprising a sequence as set forth in SEQ ID NO:4.

### Generation and Genetic Engineering of Nucleic Acids

This invention provides novel PCR primers for the amplification of nucleic acids encoding olfactory receptor ligand binding regions and libraries of these nucleic acids. The invention also provides novel libraries of expression vectors that are used to infect or transfect cells for the functional expression of these libraries. As the genes and vectors of the invention can be made and expressed *in vitro* or *in vivo*, the invention provides for a variety of means of making and expressing these genes and vectors. One of skill will recognize that desired phenotypes for altering and controlling nucleic acid expression can be obtained by modulating the expression or activity of the genes and nucleic acids (e.g., promoters,

enhancers and the like) within the vectors of the invention. Any of the known methods described for increasing or decreasing expression or activity can be used for this invention. The invention can be practiced in conjunction with any method or protocol known in the art, which are well described in the scientific and patent literature.

#### General Techniques

The nucleic acid sequences of the invention and other nucleic acids used to practice this invention, whether RNA, cDNA, genomic DNA, vectors, viruses or hybrids thereof, may be isolated from a variety of sources, genetically engineered, amplified, and/or expressed recombinantly. Any recombinant expression system can be used, including, in addition to mammalian cells, e.g., bacterial, yeast, insect or plant systems.

Alternatively, these nucleic acids can be synthesized *in vitro* by well-known chemical synthesis techniques, as described in, e.g., Carruthers (1982) Cold Spring Harbor Symp. Quant. Biol. 47:411-418; Adams (1983) J. Am. Chem. Soc. 105:661; Belousov (1997) Nucleic Acids Res. 25:3440-3444; Frenkel (1995) Free Radic. Biol. Med. 19:373-380; Blommers (1994) Biochemistry 33:7886-7896; Narang (1979) Meth. Enzymol. 68:90; Brown (1979) Meth. Enzymol. 68:109; Beaucage (1981) Tetra. Lett. 22:1859; U.S. Patent No. 4,458,066. Double stranded DNA fragments may then be obtained either by synthesizing the complementary strand and annealing the strands together under appropriate conditions, or by adding the complementary strand using DNA polymerase with an appropriate primer sequence.

Techniques for the manipulation of nucleic acids, such as, e.g., generating mutations in sequences, subcloning, labeling probes, sequencing, hybridization and the like are well described in the scientific and patent literature, see, e.g., Sambrook, ed., MOLECULAR CLONING: A LABORATORY MANUAL (2ND ED.), Vols. 1-3, Cold Spring Harbor Laboratory, (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Ausubel, ed. John Wiley & Sons, Inc., New York (1997); LABORATORY TECHNIQUES IN BIOCHEMISTRY AND MOLECULAR BIOLOGY: HYBRIDIZATION WITH NUCLEIC ACID PROBES, Part I. Theory and Nucleic Acid Preparation, Tijssen, ed. Elsevier, N.Y. (1993).

Nucleic acids, vectors, capsids, polypeptides, and the like can be analyzed and quantified by any of a number of general means well known to those of skill in the art. These include, e.g., analytical biochemical methods such as NMR, spectrophotometry, radiography, electrophoresis, capillary electrophoresis, high performance liquid chromatography (HPLC),

thin layer chromatography (TLC), and hyperdiffusion chromatography, various immunological methods, e.g. fluid or gel precipitin reactions, immunodiffusion, immunoelectrophoresis, radioimmunoassays (RIAs), enzyme-linked immunosorbent assays (ELISAs), immuno-fluorescent assays, Southern analysis, Northern analysis, dot-blot analysis, gel electrophoresis (e.g., SDS-PAGE), RT-PCR, quantitative PCR, other nucleic acid or target or signal amplification methods, radiolabeling, scintillation counting, and affinity chromatography.

#### *Amplification of Nucleic Acids*

The invention provides oligonucleotide primers that can amplify nucleic acid encoding an olfactory receptor ligand-binding region. The nucleic acids of the invention can also be cloned or measured quantitatively using amplification techniques. Using the exemplary degenerate primer pair sequences of the invention (see below), the skilled artisan can select and design suitable oligonucleotide amplification primers. Amplification methods are also well known in the art, and include, e.g., polymerase chain reaction, PCR (PCR PROTOCOLS, A GUIDE TO METHODS AND APPLICATIONS, ed. Innis, Academic Press, N.Y. (1990) and PCR STRATEGIES (1995), ed. Innis, Academic Press, Inc., N.Y., ligase chain reaction (LCR) (see, e.g., Wu (1989) Genomics 4:560; Landegren (1988) Science 241:1077; Barringer (1990) Gene 89:117); transcription amplification (see, e.g., Kwoh (1989) Proc. Natl. Acad. Sci. USA 86:1173); and, self-sustained sequence replication (see, e.g., Guatelli (1990) Proc. Natl. Acad. Sci. USA 87:1874); Q Beta replicase amplification (see, e.g., Smith (1997) J. Clin. Microbiol. 35:1477-1491), automated Q-beta replicase amplification assay (see, e.g., Burg (1996) Mol. Cell. Probes 10:257-271) and other RNA polymerase mediated techniques (e.g., NASBA, Cingene, Mississauga, Ontario); see also Berger (1987) Methods Enzymol. 152:307-316; Sambrook; Ausubel; U.S. Patent Nos. 4,683,195 and 4,683,202; Sooknanan (1995) Biotechnology 13:563-564.

Once amplified, the libraries can be cloned, if desired, into any of a variety of vectors using routine molecular biological methods; methods for cloning *in vitro* amplified nucleic acids are described, e.g., U.S. Pat. No. 5,426,039. To facilitate cloning of amplified sequences, restriction enzyme sites can be "built into" the PCR primer pair. For example, Pst I and Bsp E1 sites were designed into the exemplary primer pairs of the invention. These particular restriction sites were chosen because they have a sequence that, when ligated, are "in-frame" with respect to the 7-membrane receptor "donor" coding sequence into which

they are spliced (the odorant/ligand binding region-coding sequence is internal to the 7-membrane polypeptide, thus, if it is desired that the construct be translated downstream of a restriction enzyme splice site, out of frame results should be avoided; this may not be necessary if the inserted odorant/ligand binding domain comprises substantially most of the transmembrane VII region). The primers can be designed to retain the original sequence of the "donor" 7-membrane receptor (the Pst I and Bsp E1 sequence in the primers of the invention generate an insert that, when ligated into the Pst I/Bsp E1 cut vector, encode residues found in the "donor" mouse olfactory receptor M4 sequence). Alternatively, the primers can encode amino acid residues that are conservative substitutions (e.g., hydrophobic for hydrophobic residue, see above discussion) or functionally benign substitutions (e.g., do not prevent plasma membrane insertion, cause cleavage by peptidase, cause abnormal folding of receptor, and the like).

#### *Degenerate Primer Design*

The primer pairs of the invention are designed to selectively amplify odorant/ligand-binding regions of olfactory receptor proteins. These domain regions may vary for different odorants; thus, what may be a minimal binding region for one odorant may be too limiting for a second potential ligand. Thus, the invention includes amplification of domain regions of different sizes comprising different domain structures; for example, transmembrane (TM) domains II through VII, III through VII, III through VI or II through VI, or variations thereof (e.g., only a subsequence of a particular domain, mixing the order of the domains, and the like), of a 7-transmembrane olfactory receptor. As domain structures and sequence of many 7-membrane proteins, particularly olfactory receptors, are known, the skilled artisan can readily select domain-flanking and internal domain sequences as model sequences to design degenerate amplification primer pairs. For example, a nucleic acid sequence encoding domain regions II through VII can be generated by PCR amplification using a primer pair SEQ ID NO:1 and SEQ ID NO:2 (see Figure 1). To amplify a nucleic acid comprising transmembrane domain I (TM I) sequence, a degenerate primer can be designed from a nucleic acid that encodes the amino acid sequence LFLLYL 3' (SEQ ID NO:49). Such a degenerate primer can be used to generate a binding domain incorporating TM I through TM III, TM I through TM IV, TM I through TM V, TM I through TM VI or TM I through TM VII).

To amplify a nucleic acid comprising a transmembrane domain III (TM III) sequence, a degenerate primer (of at least about 17 residues) can be designed from a nucleic acid that encodes the amino acid sequence M(A/G)(Y/F)DRYVAI 3' (SEQ ID NO:50 (encoded by a nucleic acid sequence such as 5'-ATGG(G/C)CT(A/T)TGACCG (C/A/T)T(AT)(C/T)GT-3' (SEQ ID NO:51)). Such a degenerate primer can be used to generate a binding domain incorporating TM III through TM IV, TM III through TM V, TM III through TM VI or TM III through TM VII.

To amplify transmembrane domain VI (TM VI) sequence, a degenerate primer (of at least about 17 residues) can be designed from nucleic acid encoding an amino acid sequence TC(glycine/Alanine)SHL (SEQ ID NO:52), encoded by a sequence such as 5'-AG(G/A)TGN(G/C)(T/A)N(G/C)C(G/A)CANGT-3' 3' (SEQ ID NO:53), Such a degenerate primer can be used to generate a binding domain incorporating TM I through TM VI, TM II through TM VI, TM III through TM VI or TM IV through TM VI).

Paradigms to design degenerate primer pairs are well known in the art. For example, a COnsensus-DEgenerate Hybrid Oligonucleotide Primer (CODEHOP) strategy computer program is accessible as <http://blocks.fhcrc.org/codehop.html>, and is directly linked from the BlockMaker multiple sequence alignment site for hybrid primer prediction beginning with a set of related protein sequences, as known olfactory receptor ligand binding regions (see, e.g., Rose (1998) Nucleic Acids Res. 26:1628-1635; Singh (1998) Biotechniques 24:318-319).

Means to synthesize oligonucleotide primer pairs are well known in the art. "Natural" base pairs or synthetic base pairs can be used. For example, use of artificial nucleobases offers a versatile approach to manipulate primer sequence and generate a more complex mixture of amplification products. Various families of artificial nucleobases are capable of assuming multiple hydrogen bonding orientations through internal bond rotations to provide a means for degenerate molecular recognition. Incorporation of these analogs into a single position of a PCR primer allows for generation of a complex library of amplification products. See, e.g., Hoops (1997) Nucleic Acids Res. 25:4866-4871. Nonpolar molecules can also be used to mimic the shape of natural DNA bases. A non-hydrogen-bonding shape mimic for adenine can replicate efficiently and selectively against a nonpolar shape mimic for thymine (see, e.g., Morales (1998) Nat. Struct. Biol. 5:950-954). For example, two degenerate bases can be the pyrimidine base 6H, 8H-3,4-dihydropyrimido[4,5-c][1,2]oxazin-

7-one or the purine base N6-methoxy-2,6-diaminopurine (see, e.g., Hill (1998) Proc. Natl. Acad. Sci. USA 95:4258-4263). Exemplary degenerate primers of the invention incorporate the nucleobase analog 5'-Dimethoxytrityl-N-benzoyl-2'-deoxy-Cytidine,3'-[(2-cyanoethyl)-(N,N-diisopropyl)]-phosphoramidite (( the term "P" in the sequences, see above). This  
 5 pyrimidine analog hydrogen bonds with purines, including A and G residues.

Exemplary primer pairs for amplification of olfactory receptor transmembrane domains II through VII include:

(a) 5'-GGGGTCCGGAG(A/G)(C/G)(A/G)TA(A/G/T)AT(A/G/P)A(A/G/P)(A/G/P)GG-3'  
 (SEQ ID NO:1) and

10 5'-GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)TT(C/T)(C/T)T-3'  
 (SEQ ID NO:2).

(b) 5'-GGGGTCCGGAG(A/G)(C/G)T(A/G)A(A/G/T)AT(A/G/P)A(A/G/P)(A/G/P)GG-3'  
 (SEQ ID NO:7) and

15 5'-GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)TT(C/T)(C/T)T-3'  
 (SEQ ID NO:8)

(c) 5'-GGGGTCCGGAG(A/G)(C/G)T(A/G)A(A/G/T)AT(A/G/C/T)A(A/G/C/T)  
 (A/G/C/T)GG-3' (SEQ ID NO:9) and

20 5'-GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)TT(C/T)(C/T)T-3'  
 (SEQ ID NO:10).

### *Generating Nucleic Acids from Olfactory Receptor-Expressing Cells*

The invention provides method for generating nucleic acids that encode ligand-binding regions of olfactory receptors by amplification (e.g., PCR) of appropriate nucleic acid sequences using degenerate primer pairs. The amplified nucleic acid can be  
 25 genomic DNA from any cell or tissue or mRNA or cDNA derived from olfactory receptor-expressing cells, e.g., olfactory neurons or olfactory epithelium.

Isolation of from olfactory receptor-expressing cells is well known in the art (cells expressing naturally or inducibly expressing olfactory receptors can be used to express the hybrid olfactory receptors of the invention to screen for potential odorants and odorant  
 30 effect on cell physiology, as described below). For example, cells can be identified by olfactory marker protein (OMP), an abundant cytoplasmic protein expressed almost exclusively in mature olfactory sensory neurons (see, e.g., Buiakova (1996) Proc. Natl. Acad.

Sci. USA 93:9858-9863). Shirley (1983) Eur. J. Biochem. 32:485-494, describes a rat olfactory preparation suitable for biochemical studies *in vitro* on olfactory mechanisms. Cultures of adult rat olfactory receptor neurons are described by Vargas (1999) Chem. Senses 24:211-216. Because these cultured neurons exhibit typical voltage-gated currents and are responsive to application of odorants, they can also be used to express the hybrid olfactory receptors of the invention for odorant screening (endogenous olfactory receptor can be initially blocked, if desired, by, e.g., antisense, knockout, and the like). U.S. Patent No. 5,869,266 describes culturing human olfactory neurons for neurotoxicity tests and screening. Murrell (1999) J. Neurosci. 19:8260-8270 describes differentiated olfactory receptor-expressing cells in culture that respond to odorants, as measured by an influx of calcium.

*Genetic engineering of hybrid receptor-encoding sequences*

The invention provides hybrid protein-coding sequences comprising polypeptide-encoding nucleic acids fused to the translocation sequences of the invention. Also provided are hybrid olfactory receptors comprising the translocation motifs and odorant/ligand-binding domains of olfactory receptors. These nucleic acid sequences can be operably linked to transcriptional or translational control elements, e.g., transcription and translation initiation sequences, promoters and enhancers, transcription and translation terminators, polyadenylation sequences, and other sequences useful for transcribing DNA into RNA. In construction of recombinant expression cassettes, vectors, transgenics, of the invention, a promoter fragment can be employed to direct expression of the desired nucleic acid in all tissues. Olfactory cell-specific transcriptional elements can also be used to express the fusion polypeptide receptor of the invention, including, e.g., a 6.7 kb region upstream of the M4 olfactory receptor coding region. This region was sufficient to direct expression in olfactory epithelium with wild type zonal restriction and distributed neuronal expression for endogenous olfactory receptors (Qasba (1998) J. Neurosci. 18:227-236). Receptor genes are normally expressed in a small subset of neurons throughout a zonally restricted region of the sensory epithelium. The transcriptional or translational control elements can be isolated from natural sources, obtained from such sources as ATCC or GenBank libraries, or prepared by synthetic or recombinant methods.

The invention provides fusion proteins comprising the translocation motif of the invention. However, these fusion proteins can also comprise additional element for, e.g., protein detection, purification, or other applications. Detection and purification facilitating

domains include, e.g., metal chelating peptides such as polyhistidine tracts or histidine-tryptophan modules or other domains that allow purification on immobilized metals; maltose binding protein; protein A domains that allow purification on immobilized immunoglobulin; or the domain utilized in the FLAGS extension/affinity purification system (Immunex Corp, Seattle WA).

The inclusion of a cleavable linker sequences such as Factor Xa (see, e.g., Ottavi (1998) Biochimie 80:289-293), subtilisin protease recognition motif (see, e.g., Polyak (1997) Protein Eng. 10:615-619); enterokinase (Invitrogen, San Diego CA), and the like, between a translocation domain of the invention (for efficient plasma membrane expression) and the rest of the newly translated polypeptide may be useful to facilitate purification. For example, one construct can include a polypeptide-encoding nucleic acid sequence linked to six histidine residues followed by a thioredoxin, an enterokinase cleavage site (see, e.g., Williams (1995) Biochemistry 34:1787-1797), and an amino terminal translocation domain. The histidine residues facilitate detection and purification while the enterokinase cleavage site provides a means for purifying the desired protein(s) from the remainder of the fusion protein. Technology pertaining to vectors encoding fusion proteins and application of fusion proteins are well described in the scientific and patent literature, see e.g., Kroll (1993) DNA Cell. Biol., 12:441-53.

#### *Cloning and construction of expression vectors*

The invention provides libraries of expression vectors comprising the olfactory binding domain-encoding sequences of the invention. These nucleic acids may be introduced into a genome or into the cytoplasm or a nucleus of a cell and expressed by a variety of conventional techniques, well described in the scientific and patent literature. See, e.g., Roberts (1987) Nature 328:731; Berger (1987) supra; Schneider (1995) Protein Expr. Purif. 6435:10; Sambrook, Tijssen or Ausubel. Product information from manufacturers of biological reagents and experimental equipment also provide information regarding known biological methods. The vectors can be isolated from natural sources, obtained from such sources as ATCC or GenBank libraries, or prepared by synthetic or recombinant methods.

The nucleic acids of the invention can be expressed in expression cassettes, vectors or viruses which are stably or transiently expressed in cells (e.g., episomal expression systems). Selection markers can be incorporated into expression cassettes and vectors to



confer a selectable phenotype on transformed cells and sequences. For example, selection markers can code for episomal maintenance and replication such that integration into the host genome is not required. For example, the marker may encode antibiotic resistance (e.g., chloramphenicol, kanamycin, G418, bleomycin, hygromycin) or herbicide resistance (e.g., chlorosulfuron or Basta) to permit selection of those cells transformed with the desired DNA sequences (see, e.g., Blondelet- Rouault (1997) *Gene* 190:315-317; Aubrecht (1997) *J. Pharmacol. Exp. Ther.* 281:992-997). Because selectable marker genes conferring resistance to substrates like neomycin or hygromycin can only be utilized in tissue culture, chemoresistance genes are also used as selectable markers *in vitro* and *in vivo*.

### Structure of Seven-Transmembrane Receptors

The invention provides a chimeric nucleic acid sequence encoding an odorant/ligand binding domain within any 7-transmembrane polypeptide. 7-transmembrane receptors belong to a superfamily of transmembrane (TM) proteins having seven domains that transverse a plasma membrane seven times. Each of the seven domains spans the plasma membrane (TM I to TM VII). Because 7-transmembrane receptor polypeptides have similar primary sequences and secondary and tertiary structures, structural domains (e.g., TM domains) can be readily identified by sequence analysis. For example, homology modeling, Fourier analysis and helical periodicity detection can identify and characterize the seven domains within a 7-transmembrane receptor sequence. Fast Fourier Transform (FFT) algorithms can be used to assess the dominant periods that characterize profiles of the hydrophobicity and variability of analyzed sequences. To predict TM domains and their boundaries and topology, a "neural network algorithm" by "PHD server" can be used, as done by Pilpel (1999) *Protein Science* 8:969-977; Rost (1995) *Protein Sci.* 4:521-533. Periodicity detection enhancement and alpha helical periodicity index can be done as by, e.g., Donnelly (1993) *Protein Sci.* 2:55-70. Other alignment and modeling algorithms are well known in the art, see, e.g., Peitsch (1996) *Receptors Channels* 4:161-164; Cronet (1993) *Protein Eng.* 6:59-64 (homology and "discover modeling"); <http://bioinfo.weizmann.ac.il/>.

### *Olfactory gene and receptors*

The library sequences of the invention include receptor sequences that correspond to TM ligand-binding domains, including, e.g., TM II to VII, TM II to VI, TM III

to VII, and TM III to VII, that have been amplified (e.g., PCR) from mRNA of or cDNA derived from, e.g., olfactory receptor-expressing neurons or genomic DNA. Olfactory (or "odorant") receptors belong to the 7-transmembrane receptor superfamily; however they are also recognized as a distinct family of receptors. Olfactory receptors are G-protein-coupled receptors (Raming (1993) Nature 361:353-356). Genes encoding the olfactory receptors are active primarily in olfactory neurons (Axel (1995) Sci. Amer. 273:154-159). Individual olfactory receptor types are expressed in subsets of cells distributed in distinct zones of the olfactory epithelium (Breer (1994) Semin. Cell Biol. 5:25-32). The human genome contains thousands of genes that encode a diverse repertoire of olfactory receptors (Rouquier (1998) Nat. Genet. 18:243-250; Trask (1998) Hum. Mol. Genet. 7:2007-2020).

*Identifying olfactory receptor TM domain structures and sequences*

The invention provides libraries of olfactory receptor odorant/ligand-binding TM domain sequences. These sequence can include a various TM domains or variations thereof, as describe above. These sequences can be derived from any 7-transmembrane receptor. Because these polypeptides have similar primary sequences and secondary and tertiary structures, the seven domains can be identified by various analyses well known in the art, including, e.g., homology modeling, Fourier analysis and helical periodicity (see, e.g., Pilpel (1999) supra), as described above. Using this information sequences flanking the seven domains can be identified and used to designed degenerate primers for amplification of various combinations of TM regions and subsequences for use in the compositions and methods of the invention.

**Measuring Changes in Physiologic Activity Due to Olfactory Receptor-Ligand Binding**

The invention provides methods and compositions for determining whether a test compound specifically binds to a mammalian olfactory receptor *in vitro* or *in vivo*. The invention also provides methods and compositions for determining whether a test compound is neurotoxic to an olfactory neuron expressing an olfactory transmembrane receptor polypeptide. Any aspect of cell physiology can be monitored to assess the effect of odorant/ligand binding to a chimeric olfactory receptor of the invention.

Olfactory receptors are normally located on the specialized cilia of olfactory neurons. These receptors bind odorants and initiate the transduction of chemical stimuli into electrical signals. This process can involve a G protein-coupled activation of an adenylyl cyclase, which leads to a rise in cAMP and consequently the opening of cyclic nucleotide-

activated, non-selective cation channels. These open channels produce a cation influx that results in the depolarization of the olfactory neuron. Another olfactory transduction mechanism can also include the generation of IP<sub>3</sub> and the opening of IP<sub>3</sub>-activated channels on the ciliary plasma membrane. Electro-olfactograms can measure the mass response of sensory neurons in the olfactory epithelium (discussed below).

#### *Cell Culture Assays*

The invention provides methods and compositions for expressing the chimeric olfactory receptors of the invention in cells to screen for odorants that can specifically bind and the effect (e.g., biochemical or electrophysiological) of such binding on cell physiology. Any cell expression system can be used, e.g., mammalian cell expression systems. Cells that normally express olfactory receptors can be used, particularly to study the physiological effect of an odorant on a cell. Isolation and/or culturing of such cells and their transformation with chimeric olfactory receptor-expressing sequences of the invention can be done with routine methods, as described above. See, e.g., description of cultured neurons that exhibit typical voltage-gated currents and are responsive to application of odorants. Vargan (1999) supra; olfactory neurons from rats (Coon (1989) Proc. Natl. Acad. Sci. USA 86:1703-1707). However, the neurotoxicity of various agents to humans could be more accurately determined using cultured human neurons than cultured non-human neurons.

To evaluate electrophysiologic effects of ligand binding to cell-expressed chimeric receptor, patch-clamping of individual cells can be done. Patch-clamp recordings of the olfactory receptor cell membrane can measure membrane conductances. Some conductances are gated by odorants in the cilia and depolarize the cell through cAMP- or IP<sub>3</sub>-sensitive channels, depending on the species. Other conductances are activated by membrane depolarization and/or an increased intracellular Ca<sup>2+</sup> concentration. See, e.g., Trotier (1994) Semin. Cell Biol. 5:47-54.

Changes in calcium ion levels in the cell after exposure of the cell to known or potential odorant/ligands can be accomplished by a variety of means. For example, cells can be pre-loaded with reagents sensitive to calcium ion transients, e.g., Fura-2 (see, e.g., Rawson (1997) J. Neurophysiol. 77:1606-1613; Restrepo (1996) J. Neurobiol. 30:37-48). Measurement of calcium transients is described in detail in Example 1, below. For example, Kashiwayanagi (1996) Biochem. Biophys. Res. Commun. 225:666-671 measured both of

inositol 1,4,5-trisphosphate induces inward currents and  $\text{Ca}^{2+}$  uptake in frog olfactory receptor cells.

Other physiologic mechanisms can also be measured, e.g., plasma membrane homeostasis parameters (including lipid second messengers), cellular pH changes (see, e.g., Silver (1998) Methods Cell Biol. 56:237-251), G proteins (see, e.g., Quartara (1997) Neuropeptides 31:537-563); cAMP, and the like.

#### *Non-human animal assays*

The invention also provides non-human animals expressing one or more hybrid olfactory receptor sequences of the invention, particularly human olfactory receptor sequences. Such expression can be used to determine whether a test compound specifically binds to a mammalian olfactory transmembrane receptor polypeptide *in vivo* by contacting a non-human animal stably or transiently infected with a nucleic acid derived from the library of the invention with a test compound and determining whether the animal reacts to the test compound by specifically binding to the receptor polypeptide.

Use of the translocation domains of the invention in the fusion polypeptides generates a cell expressing high levels of olfactory receptor. Animals infected with the vectors of the invention are particularly useful for assays to identify and characterize odorants/ligands that can bind to a specific or sets of receptors. Such vector-infected animals expressing libraries of human olfactory sequences can be used for *in vivo* screening of odorants and their effect on, e.g., cell physiology (e.g., on olfactory neurons), on the CNS (e.g., olfactory bulb activity), or behavior.

Means to infect/express the libraries of nucleic acids and vectors of the invention are well known in the art, as described above. A variety of individual cell, organ or whole animal parameters can be measured by a variety of means. For example, recording of stimulant-induced waves (bulbar responses) from the main olfactory bulb or accessory olfactory bulb is a useful tool for measuring quantitative stable olfactory responses. When electrodes are located on the olfactory bulb surface it is possible to record stable responses over a period of several days (see, e.g., Kashiwayanagi (1997) Brain Res. Brain Res. Protoc. 1:287-291). In this study, electroolfactogram recordings were made with a four-electrode assembly from the olfactory epithelium overlying the endoturbinates facing the nasal septum. Four electrodes were fixed along the dorsal-to-ventral axis of one turbinate bone or were placed in corresponding positions on four turbinate bones and moved together up

toward the top of the bone. See also, Scott (1997) J. Neurophysiol. 77:1950-1962; Scott (1996) J. Neurophysiol. 75:2036-2049; Ezeh (1995) J. Neurophysiol. 73:2207-2220. In other systems, fluorescence changes in nasal epithelium can be measured using the dye di-4-ANEPPS, which is applied on the rat's nasal septum and medial surface of the turbinates (see, e.g., Youngentob (1995) J. Neurophysiol. 73:387-398). Extracellular potassium activity (aK) measurements can also be carried out in *in vivo*. An increase in aK can be measured in the mucus and the proximal part of the nasal epithelium (see, e.g., Khayari (1991) Brain Res. 539:1-5).

The chimeric olfactory receptor of the invention can be expressed in animal nasal epithelium by delivery with an infecting agent, e.g., adenovirus expression vector. Recombinant adenovirus-mediated expression of a recombinant gene in olfactory epithelium using green fluorescent protein as a marker is described by, e.g., Touhara (1999) Proc. Natl. Acad. Sci. USA 96:4040-4045.

*Transgenic non-human animals incorporating hybrid olfactory receptors*

The invention also provides non-human animals genetically engineered to express one or more hybrid olfactory receptor sequences of the invention, particularly human olfactory receptor sequences. Because the translocation domains of the invention in the fusion polypeptides generates an animal expressing high levels of olfactory receptor, these animals and their progeny are particularly useful for assays to identify and characterize odorants/ ligands that can bind to a specific or sets of receptors.

The endogenous olfactory receptor genes can remain functional and wild-type (native) activity can still be present. In other situations, where it is desirable that all olfactory receptor activity is by the introduced exogenous hybrid receptor, use of a knockout line is preferred. Methods for the construction of non-human transgenic animals, particularly transgenic mice, and the selection and preparation of recombinant constructs for generating transformed cells are well known in the art.

Construction of a "knockout" cell and animal is based on the premise that the level of expression of a particular gene in a mammalian cell can be decreased or completely abrogated by introducing into the genome a new DNA sequence that serves to interrupt some portion of the DNA sequence of the gene to be suppressed. Also, "gene trap insertion" can be used to disrupt a host gene, and mouse embryonic stem (ES) cells can be used to produce knockout transgenic animals (see, e.g., Holzschu (1997) Transgenic Res 6: 97-106). The

insertion of the exogenous sequence is typically by homologous recombination between complementary nucleic acid sequences. The exogenous sequence is some portion of the target gene to be modified, such as exonic, intronic or transcriptional regulatory sequences, or any genomic sequence which is able to affect the level of the target gene's expression; or a combination thereof. Gene targeting via homologous recombination in pluripotential embryonic stem cells allows one to modify precisely the genomic sequence of interest. Any technique can be used to create, screen for, propagate, a knockout animal, e.g., see Bijvoet (1998) Hum. Mol. Genet. 7:53-62; Moreadith (1997) J. Mol. Med. 75:208-216; Tojo (1995) Cytotechnology 19:161-165; Mudgett (1995) Methods Mol. Biol. 48:167-184; Longo (1997) Transgenic Res. 6:321-328; U.S. Patents Nos. 5,616,491; 5,464,764; 5,631,153; 5,487,992; 5,627,059; 5,272,071; and, WO 91/09955, WO 93/09222, WO 96/29411, WO 95/31560, and WO 91/12650.

The nucleic acid libraries of the invention can also be used as reagents to produce "knockout" human cells and their progeny.

## Kits

The invention provides kits that contain degenerate primer pairs of the invention. cDNA libraries from olfactory epithelium can also be included. The kits can contain recombinant adenoviruses comprising a single construct or libraries of expression vectors of the invention. The kit can also contain replication-competent cells, such as 293 cells. The kit can contain instructional material teaching methodologies, e.g., means to amplify nucleic acid, infect animals, and the like.

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims.

## EXAMPLES

The following examples are offered to illustrate, but not to limit the claimed invention.

**Example 1:** Identification of odorant/ligands for olfactory receptors with binding sites generated by PCR amplification with degenerate primers by functional expression of libraries of the receptors in human cell lines

The following example sets forth the generation of an expression plasmid library containing a large and diverse repertoire of nucleic acids encoding odorant/ligand binding regions comprising transmembrane (TM) II-VII regions of mouse olfactory receptor sequences. From this library, 80 chimeric receptors were tested against 26 odorants after transient transfection into the human cell line HEK-293. Three receptors were identified that responded to micromolar concentrations of carvone, (-) citronellal and limonene, respectively.

A PCR-based amplification strategy taking advantage of the homology shared among olfactory receptors at the beginning of TM II and the end of TM VII was used to generate a library containing a large number of olfactory-receptor sequences. The structure of the overall construct, pCMV-Rho/M4<sub>NC</sub>, is shown in figure 1A. The degenerate oligonucleotides are flanked by the coding sequences for the appropriate regions of the mouse M4 olfactory receptor (described by, e.g., Qasba (1998) J. Neurosci. 18:227-236).

*Making a chimeric receptor cassette and vector for eukaryotic expression*

Chimeric receptor expression vectors were assembled from a pBK-CMV plasmid (Stratagene, San Diego, CA) modified such that the lac Z sequences between nucleotides 1098 and 1300 were deleted. A PCR fragment consisting of 45 nucleotides upstream of the bovine rhodopsin initiation codon and the first 60 nucleotides of the coding region (designated "rho-tag" in Figure 1A) was introduced between the BamHI and EcoRI sites. Restriction fragments corresponding to the first 57 amino acids (the N-terminus to TM II, EcoRI/PstI restriction sites) (SEQ ID NO:1) and to the last 22 amino acids (BspEI/XbaI restriction sites) (SEQ ID NO:2) of the mouse M4 olfactory receptor were cloned into the rhodopsin-tag ("rho-tag") vector. The resulting vector (designated pCMV-Rho/M4<sub>NC</sub>) possesses unique PstI and BspEI sites at the beginning of TM II and the end of TM VII, respectively (see Fig. 1A).

*PCR amplification*

The mouse olfactory-receptor transmembrane II-VII library was amplified using PCR. The PCR reaction mixture contained: Taq and Pfu polymerase (Stratagene, San Diego, CA) 0.5U each, 0.2mM dNTP, 1μM of each primer (degenerate oligonucleotides SEQ ID NO:1 and SEQ ID NO:2) and either 100 ng mouse genomic DNA (β<sub>2</sub>-adrenergic receptor sequence), 10 ng plasmid template DNA, or 50 to 100 ng 1<sup>st</sup> strand cDNA template prepared from mouse C57BL/6J olfactory epithelium. One amplification protocol was one cycle of 2

min at 94°C; 30 cycles at (55°C, 72°C, 94°C), 1 min each; 1 cycle at (55°C, 72°C), 10 min. A second amplification protocol was 1 cycle for 2 min at 94°C; 34 cycles at (45°C, 72°C, 94°C), 1 min each; and 1 cycle at (45°C, 72°C), 10 min. The second protocol, having a lower hybridization temperature (45°C versus 55°C) generated an equally diverse library of binding domains. A library of PCR products of about 0.7 kilobase was generated.

*Analysis of amplified odorant/ligand-binding sequence library*

Sequencing and sequence identity analysis of 26 randomly chosen PCR amplification products was performed. Deduced amino acid sequences were aligned by the ClustalW algorithm using default values established by DNASTAR alignment software (DNASTAR, Inc., Madison, WI) (see, e.g., Burland (2000) Methods Mol. Biol. 132:71-91).

This analysis revealed that all but three of the sequenced odorant/ligand binding region inserts were distinct polypeptide-coding receptor sequences. Exemplary odorant/ligand binding region nucleic acid sequences generated by amplification of *Mus musculus* cDNA, and the respective deduced amino acid sequences, include

(a)

```

1 agtgtcttat ccattctgga tatgggctat gtcaccacca cagtgcccca gatgctggta
61 catctgggtct gtaagaagaa gaccatatcc tatgttggat gtgtggctca gatgtacatc
121 ttcttgatgc tgggaatcac cgagtcttgg ctgtttgcaa tcatggccta tgataggtat
181 gtggccattt gccatcccct cagatacaaa gtcacatga gtcctttgct gcgcgggtca
241 ctggtagcct tctgtgggtt ctggggatc acctgtgccc tgatatatac tgtttctgct
301 atgattcttc cctactgtgg ccccaatgag atcaaccact tcttctgtga agtgccctgct
361 gtccctgaagc tggcctgcgc agacacctc ccaatgacc aggtagactt catcctaggc
421 tttatccttc ttttggctcc actctccctc atcattgttg tctacatcaa tatctttgct
481 gctatcttga gaatccgttc aactcaaggg aggatcaagg ccttctccac ctgtgtgtcc
541 cacatcactg tggtcacat gttctccatc ccgtgtatgg ttatgtatat gaggcctggc
601 tctgagtcct cccagaaga ggacaagaag ttggctctgt tctacaacgt catctctgcc
661 ttctcaac (SEQ ID NO:11)

```

with a deduced amino acid sequence

```

SVLSILDMGYVTTTVPQMLVHLVCKKKTISYVGCVAQMYIFLML
GITESWLFAIMAYDRYVAICHPLRYKVMSPLLRGSLVAFCGFWGITCALIYTVSAMI
LPYCGPNEINHFFCEVPAVLKLACADTSPNDQVDFILGFIILLVPLSLIIVVYINIFA
AILRIRSTQGRIKAFSTCVSHITVVTMFSIPCMVMYMRPGSESSPEEDKKLALFYNVI
SAFLN (SEQ ID NO:12)

```

(b)

```

1 tgcaacctgg ccaccatgga cattgtgtgc accccctctg tgattcctaa ggccctgatt
61 ggcctagtgt ctgaagaaaa caccatctcc ttcaaaggat gcatggctca gctcttcttt
121 cttctgtggc cttgtcttc ggagctgtg ctgtcacgg tcatggccta tgaccgctat
181 gtggccatct gctttcccct gactacagc tctagaatga gccacagct ctgtggggcc
241 ctggccgtgg gtgtatggc catctgtgct gtgaatgcat ctgtgcacac tggcctgatg
301 acacggctgt cattctgtg ccccaaggc atcacccact tcttctgtga gattccccca
361 ctccctctgc tttctgtag tcccacata attaatagcg ttatgacact tgtggcagat
421 gccttttatg ggtgcacaa ctttgtgcta acctgttat cctatggctg catcattgcc
481 agtgttctgc gcatgcgttc tgctgagggc aagaggaagg ccttttctac ctgttcaccc

```



541 cacctcatcg tggctcagtg gtactactca tctgtgttct gtgcctatgt cagtcctgcc  
 601 tccagctaca gccagaaaag aagcaaagtt acctccgtgc tgtactcgat cctcagccca  
 661 accctgaac (SEQ ID NO:13)

5 with a deduced amino acid sequence

CNLATMDIVCTPSVIPKALIGLVSEENTISFKGCMAQLFFLLWS  
 LSSELLLLLTMAYDRYVAICFPLHYSSRMSPQLCGALAVGVNSICAVNASVHTGLMTR  
 10 LSFCGPKVITHFFCEIPPLLLSCSPTYINSVMTLVADAFYGCINFVLTLSSYGCIIA  
 SVLRMSAEGKRKAFSTCSSHLIVSVYYSSVFCAYVSPASSYSPERSKVTSLYSIL  
 SPTLN (SEQ ID NO:14)

(c)

1 tgcaacctgg ccaccatgga tattatctgc acctcctctg tgctgcccga ggcgctgggt  
 15 61 ggtctactat ctgaggaaaa caccatctcc tttaaagggg gcatggccca gctcttcttc  
 121 cttgtgtggg ccttctcttc agagctgctg ctgtcacag tcatggccta tgaccgctat  
 181 gtggccatct gctttcccct gcactacagc tctagaatga gccacagtt gtgtggggct  
 241 ctggccatgg gtgtatggc catctgtgct ctgaatgcat ctatcaacac tggctctgatg  
 301 acacggctgt cattctgtgg acccaaggtc atcaccact tcttctgtga gattccccca  
 20 361 ctcttctgct tctcctgtag cccacatac gtaaacagca ttatgactct aatagcagat  
 421 gtcttctatg gaggcacaa ttttgtgctt accttactat cctatggctg catcattgcc  
 481 agcatcctgc gcatgcgttc tgctgagggc aagaggaagg ccttttctac ctgctcatcc  
 541 cacctcatcg tggctcctgt gtactactca tctgtgttct gtgcctatgt cagccctgca  
 601 tccagctata gccagaaaag aagcaaagtt acctctgtgt tgtactcatt cctcagccca  
 25 661 accctgaac (SEQ ID NO:15)

with a deduced amino acid sequence

CNLATMDIICTSSVLPKALVGLLSEENTISFKGCMAQLFFLVWS  
 LSSELLLLLTMAYDRYVAICFPLHYSSRMSPQLCGALAMGVNSICALNASINTGLMTR  
 30 LSFCGPKVITHFFCEIPPLLLSCSPTYVNSIMTLIADVFGGINFVLTLSSYGCIIA  
 SILRMSAEGKRKAFSTCSSHLIVSVYYSSVFCAYVSPASSYSPERSKVTSLYSFL  
 SPTLN (SEQ ID NO:16)

(d)

1 gccacccttt cctgtgttga catcctcttc acctccacca cagtgcccaa ggccttagtg  
 35 61 aacatccaca cccaaagcag gacaatctcc tatgcaggat gcctgggcca gctctatatt  
 121 ttcttgactt ttggagacat ggacatcttt ctctggcca caatggccta tgaccgcttt  
 181 gtatgtatatt gtcacctctt ccactatagg atgatcatga gcttcagcg ctgctcactc  
 241 ttatgtacag tctgttgagc ccttacaacc gttgtggcca tgacacacac ctctctcata  
 40 301 ttccggctct ccttctgctc tcagaaggtc attccagact tcttctgtga cctgggaccc  
 361 ctaatgaaga tcgcttgctc tgaaaccgg atcaatgagc ttgtgcttct ctctctgggg  
 421 ggtgcagtca tcttaatccc ctttttcttc atccttatgt cttatatccg cattgtttca  
 481 gccatcctca gggctccttc tgcccaagga aggcgtaagg ccttttctac ctgtgggtcc  
 541 cacctttctg tgggtggcct attctttggg actgtgataa gggcttatct atgtccttca  
 45 601 tcctcttct ctaactcagt ggtagaggac acagcagcag ctgtcatgta tacagtgggtg  
 661 actcccgctg tgaac (SEQ ID NO:17)

with a deduced amino acid sequence

ATLSCVDILFTSTTPKALVNIHTQSRTISYAGCLVQLYFFLTF  
 50 GDMDIFLLATMAYDRFVAICHPLHYRMIMSFORCSLLVTVCTLTTVVAMTHTFLIFR  
 LSFCQKVPIDFFCDLGPLMKIACSETRINELVLLFLGGAVILIPFLILMSYIRIVS  
 AILRVPSAQGRKAFSTCGSHLSVVALFFGTIVIRAYLCPSSSSSNSVVEDTAAAVMYT  
 55 VVTPVLN (SEQ ID NO:18)

(e)

1 agtcagctct cctcatgga cctcatgctg gtctgtaaca ttgtgccaaa gatggcagtc

61 aacttcctgt ctggcaggaa gtccatctct tttgccggct gtggcataca aatcggattt  
 121 tttgtctctc ttgtgggata agagggcttc ttgttaggac tcatggctta tgatcgctat  
 181 gtggccatta gccaccact tcaactatccc attctcatga gccaaaagggt ctgtctccag  
 241 attgctggaa gttcctgggc ttttgggata cttgatggaa taattcagat ggtggcagcc  
 5 301 atgagcctgc cctactgtgg ctccaggtat atagatcact tcttctgtga agtgccggct  
 361 ttactgaagc tggcctgtgc agacacctcc cttttcgaca ccctgctctt tgcttgctgt  
 421 gtctttatgc tgcttcttcc tttctcgatc attgtgactt cctatgctcg catcttgggg  
 481 gctgtgctcc gtatgcactc tgcccagtc cgaaaaaagg ccctggccac ttgttctctc  
 541 cacctgacag ctgtctctct cttctacggg gcagcaatgt tcatctacct gaggccaagg  
 10 601 cgatatcgcg ctctagcca tgacaaagt gtctcaatct tctacacagt tcttactcct  
 661 atgctcaac (SEQ ID NO:19)

with a deduced amino acid sequence

SQLSLMDLMLVCNIVPKMAVNFLSGRKSISFAGCGIQIGFFVSL  
 15 VGSEGLLLGLMAYDRVAISHPLHYPIILMSQKVCLQIAGSSWAFGILDGIIQMVAAMS  
 LPYCGSRYIDHFFCEVPALLKLACADTSLFDTLFACCVFMLLLPFSIIIVTSYARILG  
 AVLRMHSAQSRKKALATCSSHLTAVSLFYGAAMFIYLRPRRYRAPSHDKVVSIFYTVL  
 TPMLN (SEQ ID NO:20)

(f)  
 1 tacaaccttt cattgtctga catgggcttt agcagcacca caatcccaa aatgctgata  
 61 aacttgcatg cacataagag atccacaaca tatgctgaat gcctaactca ggtatctttc  
 121 tttattcttt ttgggtgtat ggacagcttt ctactggcag tgatggcata tgaccgatgg  
 181 gtggccattt gtcacctct acactaccaa gtcattctga atccttgctg gtgtagatat  
 25 241 ttggttgtaa tgcatttttg tatcagtctc attgattcac aggtgcactg ctttatgggtg  
 301 tcacaactaa cattttgtac taatatagaa atccctcatt tcttctgtga tgttccagaa  
 361 cttgtaaaac ttgctgttc taacactact atcaatgaca tagccatgtt tcttcaagc  
 421 atcattgttg gattcctccc tgccctcagga atattttact cctactataa aattacttct  
 481 tctattttta gagttccatc actgttaggg aaatataaag ctttctctac ctgtggatct  
 30 541 cacctgtcag ttgtttgcct attttatgga acaggtatag gagtttacct cagttccaca  
 601 gtttctgggt cttccaggga aagtatgga gcttcggtaa tgtatacaat ggtggttcct  
 661 atgatgaac (SEQ ID NO:21)

with a deduced amino acid sequence

YNLSLSDMGFSSTTIPKMLINLHAHKRSTTYAECLTQVSFFILF  
 35 GCMDSFLLAVMAYDRWAICHPLHYQVILNPCRCRYLVMSFCISLIDSQVHCFMVSQ  
 LTFCTNIEIPHFCDVPELVKLACSNTTINDIAMFLSSIIVGFLPASGIFYSYKITS  
 SIFRVPSLLGKYKAFSTCGSHLSVVLIFYGTGIGVYLSSTVSGSSRESMVASVMYTMV  
 40 VPMMN (SEQ ID NO:22)

(g)  
 1 agtcagctct ccctcatgga cctcatgctg gtctgtaaca ttgtgcaaaa gatggcagtc  
 61 aacttcctgt ctggcaggaa gtccatctct tttgccggct gtggcataca aatcggattt  
 121 tttgtctctc ttgtgggata agagggcttc ttgttaggac tcatggctta tgatcgctat  
 45 181 gtggccatta gccaccact tcaactatccc attctcatga gccaaaagggt ctgtctccag  
 241 attgctggaa gttcctgggc ttttgggata cttgatggaa taattcagat ggtggcagcc  
 301 atgagcctgc cctactgtgg ctccaggtat atagatcact tcttctgtga agtgccggct  
 361 ttactgaagc tggcctgtgc agacacctcc cttttcgaca ccctgctctt tgcttgctgt  
 421 gtctttatgc tgcttcttcc tttctcgatc attgtgactt cctatgctcg catcttgggg  
 50 481 actgtgctcc gtatgcactc tgcccagtc cgaaaaaagg ccctggccac ttgttctctc  
 541 cacctgacag ctgtctctct cttctacggg gcagcaatgt tcatctacct gaggccaagg  
 601 cgatatcgcg ctctagcca tgacaaagt gtctcaatct tctacacagt tcttactcct  
 661 atgctcaac (SEQ ID NO:23)

with a deduced amino acid sequence

SQLSLMDLMLVCNIVPKMAVNFLSGRKSISFAGCGIQIGFFVSL

VGSEGLLLGLMAYDRYVAISHPLHYPIILMSQKVCLQIAGSSWAFGILDGIIQMVAAMS  
 LPYCGSRYIDHFFCEVPALLKLACADTSLFDTLFACCVFMLLLPFSIIIVTSYARILG  
 TVLRMHSASRKKALATCSSHLTAVSLFYGAAMFIYLRPRRYRAPSHDKVVSIFYTVL  
 TPMLN (SEQ ID NO:24)

(h)

1 tctaactctgt cctttgtgga catctgcttc acttccacca ctgttccaca gatgctggta  
 61 aacattcaca cacaagcaa ggccatcacc tatgcaggct gcatcatcca aatgtacttc  
 121 ttactgcttt tttcagggtt agacatcttt ctgctgactg tgatggccta tgaccgctat  
 181 gtggccatct gtcacccctt gcattacatg atcatcatga gcacaagacg ctgtggattg  
 241 atgattctgg catgctggat tatagggtgt ataaattccc tgttacacac ctttttgggtg  
 301 ttacggctgt cattctgcac aaacttggaa atccccatt ttttctgtga acttaataaa  
 361 gttgtacacc aggctgttc tgacaccttt cttaatgata tggtaattta cattacagct  
 421 atgctactgg ctgttggccc ctctctgtgt atcctttact cttactctag gatagtatcc  
 481 tccatttgtg caatctcttc agtgcagggg aagtacaaag cattttccac ctgtgcatct  
 541 cacctctcag ttgtctcttt attttattgc accctcctgg gagtgtacct cagctctgct  
 601 gtgacccaaa actcacatgc tactgcaaca gcttcattga tgtacactgt ggtcaccccc  
 661 atgctgaac (SEQ ID NO:25)

with a deduced amino acid sequence

SNLSFVDICFTSTTVPQMLVNIHTQSKAITYAGCIIQMYFLLLF  
 SGLDIFLLTVMAYDRYVAICHPLHYMIIMSTRRCGLMILACWIIIGVINSLLHTFLVLR  
 LSFCTNLEIPHFFCELNQVHQACSDTFLNDMVIYITAMLLAVGPFSGILYSRIVS  
 SICAISSVQGYKAFSTCASHLSVVSIFYCTLLGVYLSSAVTQNSHATATASLMYTVV  
 TPMLN (SEQ ID NO:26)

(i)

1 agtcagctct ccctcatgga cctcatgctg gtctgtaaca ttgtgcaaaa gatggcagtc  
 61 aacttcctgt ctggcaggaa gtccatctct tttgccggct gtggcataca aatcggattt  
 121 tttgtctctc ttgtgggac agagggtctc ttgttaggac tcatggctta tgatcgctat  
 181 gtggccatta gccaccact tcatatccc attctcatga gccaaaaggc ctgtctccag  
 241 attgctggaa gttcctgggc ttttgggac cttgatggaa taattcagat ggtggcagcc  
 301 atgagcctgc cctactgtgg ctccaggtat atagatcact tcttctgtga agtgccggct  
 361 ttactgaagc tggcctgtgc agacacctcc cttttcgaca ccctgctctt tgcttgcctg  
 421 gtctttatgc tgcctcttcc tttctcgatc attgtgactt cctatgctcg catcttgggg  
 481 gctgtgctcc gtatgcactc tgcccagtc cgaaaaagg ccctggccac ttgttcctcc  
 541 cacttgacag ctgtctctct cttctacggg gcagcaatgt tcatctacct gaggccaagg  
 601 cgatatcgcg ctccatagcca tgacaaaagt gtctcaatct tctacacagt tcttactcct  
 661 atgctcaac (SEQ ID NO:27)

with a deduced amino acid sequence

SQLSLMDLMLVCNIVPKMAVNFLSGRKSISFAGCGIQIGFFVSL  
 VGSEGLLLGLMAYDRYVAISHPLHYPIILMSQKVCLQIAGSSWAFGILDGIIQMVAAMS  
 LPYCGSRYIDHFFCEVPALLKLACADTSLFDTLFACCVFMLLLPFSIIIVTSYARILG  
 AVLRMHSASRKKALATCSSHLTAVSLFYGAAMFIYLRPRRYRAPSHDKVVSIFYTVL  
 TPMLN (SEQ ID NO:28)

(j)

1 tgtgccctct ccactcttga gattttctac acctttgcca tcatcccacg catgttggct  
 61 gactgctca ccacacttca ctccatcgcc tttctggcct gtgccagcca gatgttcttc  
 121 tctttcacat ttggcttcac ccattccttt ctactcaccg tcatgggcta tgaccgctac  
 181 gtggccatct gtcacccact gagatacaat gtgctcatga gccccgtgg ctgtgcctgc  
 241 ctggtagcct ggtcctgggt tgggtggatca ttcattggga cagtgggtgac gacagccatt  
 301 ttcaacctca cattctgtgg acccaatgag atccaccatt ttacttgtca tgttccacct  
 361 ctattgaagt tggcatgagg agagaatgta ctggagggtg caaagggtgt agaaatagtg  
 421 tgcacacag ccctcctggg ctgctttctc ctcatcctcc tctcatatgc cttcattgtg

481 gttaccatct tgaagatacc atcagctgag ggtcggcaca aggctttctc cacatgtgca  
 541 tcccacctca cagtgggtgt tgtacattat ggctttgctt ctgtcattta cctcaagcct  
 601 aagggcccca agtctctgga aggagatact ctgatgggca tcacctacac agtccctcacc  
 661 cccttcctta gt atgtcaac (SEQ ID NO:29)

5 with a deduced amino acid sequence

CALSISEIFYTFAIIPRLADLLTTLHSIAFLACASQMFFSFTF  
 GFTHSFLLTVMGYDRYVAICHPLRYNVLMSPRGACLVAWSWVGGSFMGTVVTTAIFN  
 LTFCGPNEIHFTCHVPPLLLKLAGENVLEVAKGVEIVCITALLGCFLILLISYAFIV  
 10 VTILKIPSAEGRHKAFSTCASHLTVVVHYGFASVIYLPKPGPKSLEGDTLMGITYTV  
 LTPFLS (SEQ ID NO:30)

(k)

1 tgcaacttag cgaccatgga tattatctgc acctcctctg tactgcccac ggcgctgggt  
 15 61 ggtctactgt ctgaggaaaa caccacctcc ttcaaagggt gcatgactca gctcttcttt  
 121 cttgtgtggt ctggatcctc tgagctgctg ctgctcacag tcatggccta tgaccgctat  
 181 gtggccatct gtttgcccct gcattacagc tctaggatga gtccacagct ctgtgggacc  
 241 tttgccgtgg gtgtatggc catctgcgca ctaaagcat ctatcaacac tggctgtatg  
 301 acacggctgt cattctgtgg cccaaggtc atcaccact tcttctgtga gattccccc  
 20 361 ctctcctctg tctcctgtag tctacatat ataaatagcg ttatgactct tgtggcagat  
 421 gccttttatg gaggcacaa ttttttactt acctgtctat cctatggctg catcattgcc  
 481 agcatcctgc gcatgcgttc tgctgagggc aagaggaagg ccttttctac ctgctcatcc  
 541 cacctcattg tggctctctg gtactactca tctgtgttct gtgcctatgt cagccctgct  
 601 tctagctaca gcccagaaag aagcaaagtt tcctcagtgc tgtactcagt cctcagccca  
 25 661 accctcaac (SEQ ID NO:31)

with a deduced amino acid sequence

CNLATMDIICTSSVLPKALVGLLSEENTTSFKGCMTQLFFLVWS  
 GSSELLLLTVMAYDRYVAICLPLHYSSRMSPQLCGTFAVGWVSICALNASINTGLMTR  
 30 LSFCGPKVITHFCEIPPLLLSCSPTYINSVMTLVADAFYGGINFLLTLLSYGCIIA  
 SILMRSAEGKRKAFSTCSSHLIVSVVYSSVFCAYVSPASSYSPERSKVSSVLYSVL  
 SPTLN (SEQ ID NO:32)

(l)

1 gccaaccttt ccttcgttga tgtctgcttc accaccaatc tcatccccag gctcctggct  
 35 61 ggccatgtgg ctggaacaag gaccatctct tatgtccact gcctaactca gacgtacttc  
 121 ctgatttctt ttgccaatgt ggacaccttt ctgctggctg ccatggccct ggacagattt  
 181 gtggccatat gctaccact acagtaccac accatcatca cccccagct ctgtgtgggg  
 241 ctggcagccg ttgtgtggat gtgctctgcc ctcactctc tgatgcacac actcctcatg  
 40 301 agcagactga gtttctgctc ctccatcccg gagatctctc acttctactg tgatgcttac  
 361 ctgctcatga agttggcctg ttcagacaca cgagtcaatc aacttgtctt cctgggagct  
 421 gtggtcctct ttgtggcccc ctgcattctc attgtggtct cttatgtccg aatcaccatg  
 481 gtggtcctcc agatccctc tgcaaagggc cggcacaaga cattttccac atgtagctca  
 541 cacttgtctg tggctactct gttctatggc acagtactgg gtatctatat acgacctcca  
 45 601 gactccttct ccaccagga cacggtagcc accatcatgt atactgtggt taccctcatg  
 661 ctgaac (SEQ ID NO:33)

with a deduced amino acid sequence

ANLSFVDVCFITNLIPRLLAGHVAGTRTISYVHCLTQTYFLISF  
 50 ANVDTFLLAAMALDRFVAICYPLQYHTIITPQLCVGLAAVWVMCSALISLMHTLLMSR  
 LSFCSISPEISHFYCDAYLLMKLACSDTRVNQLVFLGAVVLFVAPCILIVVSYVRITM  
 VVLQIPSAKGRHKTFSTCSSHLSVTLFYGTVLGIYIRPPDSFSTQDTVATIMYTVVT  
 PMLN (SEQ ID NO:34)

(m)

1 tgcaacctgg ctaccacgga tattgtgtgc acctcctctg tgattcctaa ggccttgatt  
 61 ggcctagtag ctgaggaaaa catcatcacc ttcaagggat gtatggccca gctcttcttc  
 121 cttgcatggg caacatccgc agagctgttg ctgtcacagg tcatggccta tgaccgctat  
 181 gtggctatct gctttccctt acactacagc tctaggatga gccacagct ctgtggagca  
 241 ctggccgtgg gtgtatggtc catcagtgtc gtgaatgcat ctgtgcacac tggcctgatg  
 301 acacggctgt cattctgtgg acccaaggtc atcacccact tcttctgtga gataccccc  
 361 ctccctcctgc tctcctgtag ttccacatac attaatagtg ttatgacact tgtggcagat  
 421 gtctttctgg gaggcacaa cttcatgtta accctgttat cttatggctt catcattgcc  
 481 agcatcctgc gcatgcgttc tgctgagggc aagaggaagg ccttttctac ctgctcatcc  
 541 cacctcatcg tggtttctgt gtactactca tctctgttct gtgcctatat cagccctgct  
 601 tctagctaca gccagaaaag aagcaaagt ttctcagtgc tgtactcagt cctcagccca  
 661 accctcaac (SEQ ID NO:35)

with a deduced amino acid sequence

15 CNLATTDIVCTSSVIPKALIGLVSEENIITFKGCMALFLAWA  
 TSAELLLLTVMAYDRYVAICFPLHYSSRMSPQLCGALAVGVWSISAVNASVHTGLMTR  
 LSFCGPKVITHFFCEIPPLLLSCSSTYINSVMTLVADVFLGGINFMLTLLSYGFIIA  
 SILRMRSAEGKRKAFSTCSSHLIVSVYYSSLFCAYISPASSYSPERSKVSSVLYSVL  
 SPTLN (SEQ ID NO:36)

(n)

1 agcaacctgg cttttgttga tttctgtac tctctgtca ttacaccta gatgcttggg  
 61 aatttcttgt atagcaaaaa tgccatatcc ttcaatgcat gtgctgccc gttaggctgc  
 121 tttctcacat ttatggtatc agagtgttg cttctggctt ccatggcata tgatagatat  
 181 gcagcaattt gtaaccctct attgtatatg gtcacaatgt ctctgggaat ctgcattcag  
 241 cttgtagttg tgccctatag ctatagtttc ctcatggcat tgattcacac tcttctaacc  
 301 ttccgcctat cctattgcca ttctaatac atcaatcact tctactgtga tgacatgcct  
 361 cttctcaggc taacttgtc agatactcac tacaagcagc tgtctatttt ggcctgtgct  
 421 ggaatcacat tcatttcttc tgttctgatt gtttctgtat cctacatggt cattatttct  
 481 gccattctga ggatgcgtc agctgaagga agacggaaag ccttttccac ctgtagctct  
 541 cacatgatgg cagtgcagc attctatgga actcttatct ttatgtactt acagccgagc  
 601 tctgaccatt ctcttgatac agataagatg gcctctgtct tctacacagt gatcatcccc  
 661 atgttgaac (SEQ ID NO:37)

with a deduced amino acid sequence

35 SNLAFVDFCYSSVITPKMLGNFLYSKNAISFNACAAQLGCFITF  
 MVSECLLLASMAVDYAAICNPLLYMTMSPGICIQLVVVPYSYFLMALIHTLLTFR  
 LSYCHSNIINHFCDDMPLRLTCSATHYKQLSILACAGITFISSVLIVSVSYMFIIS  
 AILRMRSAEGRRKAFSTCSSHMMAVSIFYGTILIFMYLQPSDHS�DLDKMASVFYTVI  
 40 IPMLN (SEQ ID NO:38)

(o)

1 agtcacttgt ctttcattga catgatgtac atctcaacca ttgtgccc aaatgctagt  
 61 gattatcttc tagggcaaag gactatttcc tttgtggggt gcacagctca acatttctt  
 121 tacctcacc cgggtgggagc cgagttcttt cttctggggt tcatggctta tgatcggtat  
 181 gtggccatct gcaaccact gaggtaccct gtccatcatga gccgcccggat ctgttggtat  
 241 atcatagcag gctcctgggt tgggggatct ttggatggct tctcctcac tccaatcacc  
 301 atgagtttct ctttctgtag atcacgagag attaacact tcttctgtga ggcacctgct  
 361 gtgctgaagt tggcatgtgc agacacagcc ctctatgaga cggatgatga tgtgtgctgc  
 421 gttctgtatc tgttgattcc tttctctgtg gttatctcat cctatgcgag gattctggcc  
 481 actgtctacc atatgagctc tgtggaagga aggaagaaag cgtttgctac ctgctcgtct  
 541 cacatgactg tggtaacctt gttttatggg gctgccatat acacctatat ggtaccacac  
 601 tcttaccatt ccccatcca agacaaaatt tttctgtgt tctataccat tctcacacc  
 661 atgctgaac (SEQ ID NO:39)

with a deduced amino acid sequence

SHLSFIDMMYISTIVPKMLVDYLLGQRTISFVGCTAQHFLYLTL  
 VGAFFLLGLMAYDRYVAICNPLRYPVLMSSRRICWIIAGSWFGGSLDGFLLPITMS  
 FPFCSRREINHFFCEAPAVLKLACADTALYETVMYVCCVLMMLIPFSVVISSYARILA  
 TVYHMSSEGRKKAFATCSSHMTVVTLFYGAIIYTMVPHSYHSPSQDKIFSVFYTL  
 5 TPMLN (SEQ ID NO:40)

(p)

1 tgcaacttag cgaccatgga tattatctgc acctcctctg tactgccccaa ggcgctgggt  
 61 ggtctactgt ctgaggaaaa caccatcccc ttcaaagggt gcatgactca gctcttcttt  
 121 cttgtgtggt ctggatcctc tgagctgctg ctgctcacag tcatggccta tgaccgctat  
 10 181 gtggccatct gtttgccctt gcattacagc tctaggatga gtccacagct ctgtgggacc  
 241 tttgccgtgg gtgtatggtc catctgcgca ctaaagcat ctatcaacac tggctctgatg  
 301 acacggctgt cattctgtgg ccccaaggct atcaccact tcttctgtga gattccccca  
 361 ctctctctgc tctctgtag tcctacatat ataaatagcg ttatgactct tgtggcagat  
 421 gccttttatg gaggcacaa ttttttactt accttgctat cctatggctg catcattgcc  
 15 481 agcatcctgc gcatgcgttc tgctgagggc aagaggaagg ccttttctac ctgctcatcc  
 541 caccctcatg tggctctgt gtactactca tctgtgttct gtgcctatat cagtcctggg  
 601 tccagctaca gccagaaaag aagcaaattt acctcggtt tgactcagt cctcagccca  
 661 acctcaac (SEQ ID NO:41)

with a deduced amino acid sequence

CNLTMDIICTSSVLPKALVGLLSEENTIPFKGCMQLFFLVWS  
 GSSELLLLTVMAYDRYVAICPLHYSSRMSPQLCGTFAVGWVSICALNASINTGLMTR  
 LSFCEGPKVITHFFCEIPPLLLSCLPTIYINSVMTLVADAFYGGINFLLTLLSYGCIIA  
 25 SILMRSAEGKRKAFSTCSSHLIVSVYSSVFCAYISPGSSYSPERSKFTSVLYSVL  
 SPTLN (SEQ ID NO:42)

(q)

1 gccaacctct ccagtgtcga cattagtgtt ccatctgtca ttgtcccaa ggcattgggt  
 61 aatcatatgt tgggaagcaa gtccatctct tacacggggt gtatgaccca gatctatttc  
 121 ttcatcacat tcaacaatat ggatggcttc ctctgagtg tgatggccta tgaccgctat  
 181 gtggccatct gtcaccctct ccactacacc atgatgatga gaccagact ctgtgtcctc  
 241 ctgggtggcca tatcatgggc catcacaac ctgcatgtc tcttgcatat tctctcatg  
 301 gttcgactca cttctgttc ccacaatgca gtgcaccact tcttctgtga cccctacct  
 361 atcctgaagc tctctgttc tgacaccttc atcaatgacc tgatggctt caccattggg  
 35 421 ggattggat ttatgactcc atttcatgac attattgtt cctatgccta catcttctct  
 481 aaggttctga agttaaaatc tgcccatgga ataaggaaag cctgtgcgac gtgtgggtct  
 541 caccctactg tggctcctct cttctatggg gcgacccctg gcactatat gcacccttca  
 601 tctacataca cagtgcagga cacagtggc accgtcatct tcacagtagt gacaccatg  
 661 gtcaac acctcaac (SEQ ID NO:43)

with a deduced amino acid sequence

ANLSSVDISAPSVIVPKALVNHMLGSKSISYTGCMQIYFFITF  
 NNMDGFLLSVMAYDRYVAICPLHYTMMPRLCVLLVAISWAITNLHALLHTLLMVR  
 LTFCSHNAVHFFCDPYPIKLSCSDTFINDLMVFTIGGLVFMTPFTCIIVSYAYIPS  
 45 KVLKLSAAGIRKALSTCGSHLTVVSLFYGAILGIYMHPSSYTVQDTVATVIFTVVT  
 PMVN (SEQ ID NO:44)

(r)

1 agtcacttgg ccttcacgga catctctttc tcatctgtca cagctccaaa gatgtcatg  
 61 aatatgtgta cacatagcca atccatctca catgtgggt gtgtttccca aatatatttt  
 121 ttcttattgt ttgggtgtat tgacaacttc ctctgactt ccatggccta tgacaggat  
 181 gtggccatct gccaccctct gcattatacc actatcatga gtcaaagcct ctgtgttctg  
 241 ctagtgtatg tgtctgggac atttctctct tctaattggc ttgtgcatac tcttctcttt  
 301 gctcgtctct ctcttttttag agacaacact gtccaccatt ttttctgtga tctctctgct  
 361 ttgtgaagc tgtccagctc agacactact atcaatgaac tagtaatcct cacttttagca

421 gtggtggtca tcaactgtacc attcatatgc atcctgggtt cttatggcca catggggggc  
 481 actatcctaa gaactccatc catcaagggg atctgcaaag ccttggtccac atgtggttct  
 541 catctctgtg tagtttcttt atattatgga gccattattg gggtatattt tttccctcc  
 601 tccaataata ctaatgataa agatgtcata gtagctgtgt tgtacactgt gggtacaccc  
 661 atgctgaat accctcaac (SEQ ID NO:45)

with a deduced amino acid sequence

SHLAFTDISFSSVTAPKMLMNLTHSQSISHAGCVSQIYFFLLF  
 GCIDNFLTSMAYDRYVAICHPLHYTTIMSQSLCVLLVMVSWAFSSSNGLVHTLLFAR  
 LSLFRDNTVHHFFCDLSALLKLSSSDTTINELVILTLAVVVITVPFICILVSYGHMGA  
 TILRTPSIKGIKALSTCGSHLCVVSLLYGAIIIGLYFFPSSNNTNDKDVIVAVLYTVV  
 TPMLN (SEQ ID NO:46)

(s)

1 atggcgaaca gcactactgt tactgagttt attttgctgg ggctgtcaga tgctgtgag  
 61 ctgcagggtc tcatattcct gggctttctc ctgacctact tcctcattct gctgggaaac  
 121 ttcctcatca tcttcatcac ccttggtggac aggcgccttt acaccccat gtattacttc  
 181 ctccgcaact ttgccatgct ggagatctgg ttcacctctg tcatcttccc caagatgcta  
 241 accaacaatca tcacaggaca taagaccatc tccctactag gttgtttcct ccaagcattc  
 301 ctctatttct tccttggcac cactgagttc tttctactgg cagtgatgtc ctttgacagg  
 361 tatgtggcca tttgtaaccc tttgcgttat gccaccatta tgagcaaaag agtctgtgtc  
 421 cagcttgtgt tttgctcatg gatgtctgga ttgcttctca tcatagttcc tagttcaatt  
 481 gtatttcagc agccattctg tggcccaaac atcattaatc atttcttctg tgacaacttt  
 541 ccacttatgg aactcatatg tgcagatact agcctggtag agttcctggg tttgttatt  
 601 gccaatttca gcctcctggg cactctgggt gtgactgcca cctgctatgg ccacattctc  
 661 tataccattc tacacattcc ttcagccaag gagaggaaga aagccttctc aacttgetcc  
 721 tctcatatta ttgtggtgtc tctcttctac ggcagctgta tcttcatgta tgtccggtct  
 781 ggcaagaatg gacaggggga ggatcataac aaggtggtgg cattgctcaa cactgtagtg  
 841 acaccacac tcaaccctt catctacact ctgaggaaca agcaggtgaa gcaggtattt  
 901 agggaacacg taagcaagtt ccaaaagttc agccagacgt gaaccctcaac (SEQ ID NO:47)

with a deduced amino acid sequence

MANSTTVTEFILLGLSDACELQVLIFLGFLTYFLILLGNFLII  
 FITLVDRLRYTPMYFLRNFMLEIWFSTVIFPKMLTNIITGHKTISLLGCFLQAFLY  
 FFLGTTEFFLLAVMSFDYVAICNPLRYATIMSKRVCVQLVFCSWMSGLLLIIVPSSI  
 VFQPPFCGPNIINHFFCDNFPLMELICADTSLVEFLGFVIANFSLGLTAVTATCYGH  
 ILYTILHIPSAKERKKAFTSCSHIIVVSLFYGSCIFMYVRSGKNGQGEDHNKVALL  
 NTVVPTLNPFIYTLRNKQVKQVFRHVSFKQKFSQT (SEQ ID NO:48)

Although each insert shared some sequence homology of previously characterized olfactory receptors, the sequenced receptors were all new members of the olfactory receptor family and were distributed broadly (shown in bold-type in figure 1B) across a similarity dendrogram. Also depicted in Figure 1B are ten previously cloned olfactory receptors (see, e.g., Buck (1991) Cell 65:175-187), shown in italics in figure 1B, designated I3, I8, I14, I15, I9, F5, F3, F12, F6, and I7. Thus, the arrayed receptor plasmid inserts represented a diverse library of olfactory receptor sequences amenable to expression studies, described below.

*Chimeric vector construction*

PCR products were digested with PstI and BspEI restriction enzymes before size fractionation, purification and ligation into the pCMV-Rho/M4<sub>NC</sub> vector (see Fig. 1A). The vector ligation products were transformed into *E. coli* and 480 clones were placed in 96-well plates. PCR screening revealed that >95% of the clones carried inserts of the expected size. Pools of cells from a single column of the plates (8 wells) were grown in a 50ml culture and plasmid DNA prepared. Insert-containing vectors containing: the 5'-untranslated region of the rhodopsin gene, which included its coding region for the initiation methionine and the next 19 residues; joined to a full-length cDNA for a mouse olfactory receptor (M4 or I-C6), under the control of the CMV promoter, were also prepared. The full-length coding region of olfactory receptors mI7 and I-C6 were obtained by screening a mouse (129 SV/J) genomic phage ( $\lambda$ FIX-II) library ( $2 \times 10^6$  independent clones) using  $^{32}$ P-labeled DNA fragments (of TMII through VII sequence) of the respective receptors under stringent conditions (hybridized at 0.2X SSC at 65°C). DNA fragments encoding the full-length receptors were cloned into pBluescript (Stratagene) and sequenced.

*Culture and Transient Transfection of Human Cells Expressing Olfactory Receptor*

HEK-293 cells (obtained from the ATCC) were grown in DMEM supplemented with 10% fetal bovine serum, penicillin (100U/ml), streptomycin (100 $\mu$ g/ml) and L-glutamine (2mM) in 5% CO<sub>2</sub>. Before transfection, the cells were seeded onto poly-L-lysine-coated 10.5x35x0.17mm glass coverslips (Bellco) placed in the 60mm culture dishes. Calcium phosphate-mediated transfections were performed in a 60mm dish with 3 to 4  $\mu$ g of receptor construct DNA, 1  $\mu$ g of pCIS G $\alpha$ 15 and G $\alpha$ 16 expression vector (Offermanns (1995) supra). 2  $\mu$ g of pBluescript carrier DNA, and 0.3  $\mu$ g of pRSV-T antigen expression vector (Gorman (1990) DNA and Protein Eng. Tech. 2:3-9). After 5 to 7 hr incubation, the cells were washed once with PBS containing 0.5 mM EDTA and 10% DMSO, then with PBS before continuing growth in regular media for 40-50 hr.

*Expression of receptors on the cell surface for functional ligand-binding assays*

Efficient screening of expressed olfactory receptors with a large number of ligands by functional analysis requires a robust and sensitive assay system. Although the established role of cAMP in olfactory signaling offers a biochemical approach involving measurement of cAMP production in response to odorant stimulation, an alternative, rapid assay is to co-express the cloned olfactory receptors with G protein G $\alpha$ <sub>15,16</sub> subunits (see,



e.g., Offermanns (1995) J. Biol. Chem. 270:15175-15180), which can promiscuously couple 7-transmembrane domain receptors that normally signal through other second messengers to the PIP<sub>2</sub> pathway. In this reporter system, (olfactory) receptor activation leads to the generation of an IP<sub>3</sub>-mediated increase in intracellular Ca<sup>2+</sup>, which can be measured at the single-cell level with high sensitivity and good temporal resolution using the dye FURA-2 and radiofluorometric imaging. These attributes were able to compensate for the low transfection efficiency in transient expression systems that would hinder more traditional biochemical assays.

A construct with the TM II-VII region from the  $\beta_2$ -adrenergic receptor inserted in the pCMV-Rho/M4<sub>NC</sub> vector (Rho/M4<sub>NC</sub>- $\beta_2$  TM II-VII) was co-transfected with G $\alpha_{15,16}$  into HEK-293 cells. Immunocyto-chemical localization of vector-encoded, newly translated polypeptide with a B6-30 antibody against the rhodopsin tag (directed against the N-terminal 15 residues of rhodopsin, see Hargrave (1986 Exp. Eye Res. 42:363-373) was performed. Transfected HEK 293 cells were air dried and fixed in ice-cold methanol for 10 min. The fixed cells were blocked with 1.5% goat serum in PBS for 30 minutes and then incubated for 1 hour in PBS containing 0.03% goat serum and a 1:1000 dilution of the B6-30. After washing with PBS, a FITC-coupled, polyclonal anti-mouse antibody (Vector) was used to visualize the rhodopsin-tagged protein. Images of fluorescent cells were obtained on a Zeiss 510 confocal microscope with excitation at 488nm. Results of the localization experiments indicated that a significant portion of the expressed protein appeared to be localized to the plasma membrane (10% or more of total expressed protein). These results demonstrate that the rhodopsin N-terminus-derived "translocation domain" of the invention, when expressed in the chimeric receptors, was the cause of the efficient translocation of the chimeric receptor molecules to the plasma membrane.

These transfected cells were then tested for their ability to functionally respond to ligand-receptor binding. The ligand, the adrenergic agonist isoproterenol, was "bath" applied to the transfected cells and single cell Ca<sup>2+</sup>-imaging was performed. Cells were pre-loaded with the Ca<sup>2+</sup>-sensitive fluorescent dye FURA-2 AM (Molecular Probes) by bathing in serum-free DMEM containing 4  $\mu$ M of the membrane permeant chemical for 1 hr at 37°C, then washed with a standard bath solution (130mM NaCl, 2mM CaCl<sub>2</sub>, 5mM KCl, 10mM glucose, 10mM NaHEPES/pH 7.4 at room temperature). For each experiment, a glass coverslip with FURA-2 loaded HEK 293 cells was introduced into an open-topped,

longitudinal microperfusion chamber (300  $\mu$ l bath volume mounted on a Zeiss Axiovert 135 microscope equipped with an F Fluor 40x/1.30 oil-immersion lens. The cells were superfused with test solutions typically for 30 to 40 seconds (5 ml/application) and washed out with 5ml of bath solution at the end of each application. Each test solution was freshly diluted and manually applied with a micropipette into the chamber. Because of this manual procedure, there could be several seconds of delay in actual application from electronic tick marks used to define the beginning of application in each graph. At the same time, the solution flow might not be completely laminar. In most cases, the onset of  $\text{Ca}^{2+}$  rise in response to a specific solution occurred within 15 seconds of the beginning of solution application, though longer delays were sometimes observed. Acetylcholine was applied at the end of each experiment at 10 $\mu$ M for 15-20 seconds. Ratiometric  $\text{Ca}^{2+}$  measurements were performed as described by Grynkiewicz (1985) 260:3440-3450, with modifications using the Zeiss/Attofluor-Ratiovision imaging system. At 5-second intervals, the cells were sequentially illuminated for less than 100 ms, first at 340nm and then at 380nm. Fluorescence emission at 510nm was monitored for each excitation wavelength via an intensified CCD camera. Averaged pixel intensities within 40 to 100 regions of interest, corresponding to 40 to 100 individual cells, were digitized and stored on a computer. Attofluor-Ratiovision software (Atto Instruments) was used to determine the  $\text{Ca}^{2+}$ -dependent fluorescence signal expressed as the  $F_{340}/F_{380}$  ratio. Signals from all responding cells, or all cells (negative controls) were averaged and displayed as a function of time.

Isoproterenol bath application resulted in a transient increase in intracellular  $\text{Ca}^{2+}$  in the transfected cells. The  $\text{Ca}^{2+}$  transient induced by isoproterenol was dependent on cotransfection with the  $\text{G}\alpha_{15,16}$  subunits. Cells transfected with the G protein subunits alone produced a small response to isoproterenol, presumably due to some endogenous  $\beta$ -adrenergic receptors on their surface. However, odorants such as heptanal (7-al) and octanal (8-al) had no effect.

A second application of isoproterenol frequently failed to elicit a response, possibly suggesting a rapid desensitization of the  $\text{G}\alpha_{15,16}$ -mediated signal transduction pathway. Although its mechanism is unclear, this rapid desensitization was a frequent observation with this expression system. HEK-293 cells have intrinsic muscarinic receptors coupled to the  $\text{PIP}_2$  pathway via endogenous G proteins. The rise in intracellular  $\text{Ca}^{2+}$  upon

activation of this pathway by bath-applied acetylcholine (10 $\mu$ M) served as a control in this system.

As a second test example, a Rho/M4<sub>NC</sub>-ratI7 TM II-VII chimeric construct was generated and co-expressed with G $\alpha_{15,16}$  in HEK-293 cells. A Ca<sup>2+</sup> transient was observed in the transfected cells in response to 10 $\mu$ M octanal. The transfected cell responded to 30 $\mu$ M, but not 10  $\mu$ M, of heptanal (a shorter aldehyde than octanal). The response to octanal also required the presence of G $\alpha_{15,16}$ .

As with the  $\beta_2$ -adrenergic receptor, desensitization often occurred after a positive response. For example, little or no effect was observed upon a second application of octanal, even at 30 $\mu$ M. A similar response profile was obtained with a construct in which the translocation domain of the invention (rhodopsin N-terminus) was fused to the full-length rat I7 odorant/ligand region encoding sequence. This chimeric receptor responded to octanal even at 1  $\mu$ M. The ligand specificity was not absolute; a small response was also observed to 30 $\mu$ M heptanal (similar to an *in vivo* finding by Zhao (1998) Science 279:237-242). Sometimes, the delay between the start of odorant application and the beginning of Ca<sup>2+</sup> rise could be more than 30 seconds (e.g., the first response to octanal). The reason for this relatively long delay is unknown, but it could have arisen from a non-linear, thresholding mechanism. Additional experiments in which successive applications of two odorants were separated by periods as long as 5 minutes, however, removed any possible confusion with respect to which odorant triggered a given response.

The above results validate the HEK-293 cell expression of cloned olfactory receptor sequences as a screening system for identifying unknown odorants. They also demonstrate that odorant/ligands are binding to the 7-transmembrane domain region TM II-VII of an olfactory receptor to produce a physiologic response (in these experiments, measured by Ca<sup>2+</sup> transients).

*Identification of cognate ligand-receptor pairs for the cloned receptor library*

The 7-transmembrane domain region TM II-VII expressing vector libraries of the invention were expressed in this cell expression system. Various odorant were screened for their ability to generate a physiologic response in the form of a calcium transient, as above. Eighty plasmid clones arrayed in microtiter plates were pooled into 10 groups of eight constructs each, and co-transfected with G $\alpha_{15,16}$  into HEK-293 cells. After pre-loading with FURA-2, the transfected cells were screened sequentially against each of 26 odorants:

Hedione, (-) carvone, (+) carvone, (+) citronellal, (-) citronellal, 2-methyl-4-propyl-1,3-oxalthane, methylsalicylate, pyrrolidine, quinoline, linal, cyclohexanone, acetophenone, 2-methoxy-3-methyl-pyrazine, pyrazine, 2-methoxypyrazine, isovaleric acid, isobutyric acid, triethylamine, citralva, (+) limonene, 6-aldehyde, 7-aldehyde, 8-aldehyde, 9-aldehyde, 10-aldehyde, and 11-aldehyde (Firmenich, S. A., Princeton, NJ). The odorants were stored under nitrogen. Stock solutions of the odorants were made up fresh each day in DMSO and diluted 1000-fold into the standard bath solution to give the indicated concentrations approximately 10 seconds before application in a given experiment.

All of the (twenty-six) odorants were applied at 10  $\mu$ M to induce a  $\text{Ca}^{2+}$  response as described previously. Three sample "pools" (a mixture of clones) produced transient increases in  $\text{Ca}^{2+}$  in response to the application of (-) carvone, (-) citronellal and (+) limonene, respectively. The lack of response of one pool to (+) carvone could reflect desensitization resulting from the positive response to (-) carvone occurring immediately before, or, alternatively, a stereo-specificity in ligand recognition. This desensitization could also have obscured the response to subsequent odorant applications; nonetheless, a second response to (-) carvone could still be elicited. The absence of response to (+) citronellal for another pool apparently results from a genuine stereo-specificity in ligand recognition, because there was no prior positive response that would lead to desensitization. The lack of responses to the subsequent odorants was confirmed by additional experiments with the same set of odorants but (-) where citronellal was applied last.

Next, 8 individual clones from each of these three tested pools were isolated and tested for their ability to encode receptor binding domains with specificity for the odorants identified above. Three responsive chimeric olfactory receptors were isolated; they were designated I-D3 (carvone), I-C6 (citronellal) and I-G7 (limonene). Further experiments indicated that the I-D3 receptor was responsive to both (+) and (-) carvone. The I-C6 receptor appeared to be selective for the (-) stereoisomer of citronellal. Finally, the I-G7 receptor responded to both (+) and (-) limonene at the same concentration of 10  $\mu$ M, though perhaps not as well to the (-) isomer. For each of the three isolates, control experiments indicated that the specific responses required the presence of  $\text{G}\alpha_{15,16}$  (as discussed above).

To determine if these physiologic responses were caused by ligand interaction with a full-length 7-membrane receptor, a genomic clone of the entire I-C6 receptor coding sequence was isolated and used to make a chimeric molecule incorporating the translocation

domain of the invention (the "rhodopsin tag" sequence). The full-length I-C6 receptor retained the same stereo-selectivity as a chimeric receptor construct whose only I-C6 sequence was the transmembrane domains II through VII (i.e., the odorant/ligand binding domain). Both recombinantly expressed receptors preferred the (-) isomer of citronellal; it also showed high sensitivity, responding to this chemical even at 1  $\mu$ M. The stereo-specificity was not absolute, however, in that (+) citronellal was also able to elicit a response when applied at 30  $\mu$ M and 100  $\mu$ M. By comparison, carvone and limonene elicited no responses from this receptor even at 100  $\mu$ M. Five structurally related compounds besides (-) and (+) citronellal were also tested ( +/- citral, (-) citronellyl bromide, (-) citral demethyl acetal, (-) citronellic acid and (-) citronellol), all at 30 $\mu$ M. Among these, only 30 $\mu$ M (-) citronellyl bromide elicited a small response. This compound differs from (-) citronellal by the substitution of a bromine for the oxygen atom in the aldehyde functional group. The lack of response to (-) citronellal may be due to desensitization resulting from the positive response to 30 $\mu$ M (+) citronellal immediately before. Finally, in control experiments lacking  $G\alpha_{15,16}$ , no response was observed to either (-) citronellal or (-) citronellyl bromide (figure 5C). Although these experiments do not quantitate ligand affinities, they provide a qualitative rank order of potency for binding and activating the I-C6 receptor: (-)citronellal > (+)citronellal, citronellyl bromide > 28 other odorants.

*Analysis of individual amino acid residues on receptor- odorant binding specificities*

To establish the functional expression of mouse olfactory receptors, a Rho/M4<sub>NC</sub>-mouse I7 transmembrane II-VII chimeric receptor was constructed and examined its responsiveness to several n-aliphatic aldehydes and alcohols. At 10 $\mu$ M concentrations of these odorants, the mouse receptor responded only to heptanal. As discussed above, the rat I7 chimeric receptor responded better to octanal than to heptanal in identical experiments. This difference in odorant selectivity was retained by the full-length clones of the two receptors fused to the translocation domain of the invention (the rhodopsin tag). The rat and mouse I7 receptors differ in altogether 15 amino-acid residues, three of which (K<sub>90</sub>E in the 1<sup>st</sup> extracellular loop, V<sub>206</sub>I in TM V, and F<sub>290</sub>L in TM VII) reside between transmembrane domains II and VII.

In light of the critical role of residues in transmembrane V for ligand binding in the  $\beta_2$ -adrenergic receptor, the role of residue 206 in differential ligand recognition was examined. Reciprocal valine/isoleucine substitutions were made in the full-length rat and

mouse I7 receptor sequences. These substitutions were able to switch the ligand preferences of the two receptors, namely, making the rat I7 receptor preferentially recognize heptanal and the mouse receptor preferentially recognize octanal. Interestingly, the nature of these changes, isoleucine versus valine and heptanal versus octanal, is consistent with compensatory alterations in the structures of ligand and receptor that preserve the complementarity between the two. These observations provide strong evidence for a direct role of residue 206 in the interaction between the I7 receptor and aliphatic aldehydes. These results also demonstrate that the compositions and methods of the invention can be used to analyze odorant/ligand-olfactory receptor interactions on a molecular level.

### Summary

The few studies carried out previously on identifying cognate odorant-olfactory receptor pairs have generally focused on a single receptor and examined its responsiveness to a large number of odorants or odorant mixtures. The present invention provides the means to take a different approach by generating olfactory receptor libraries to use in the screening of a large number of cloned receptors simultaneously against a large panel of individual odorants. In this way, the problem of poor expression, inefficient folding or weak coupling to second-messenger systems associated with certain receptors in a heterologous system is avoided. Moreover, screening multiple receptors against multiple odorants, greatly increases the probability of identifying responsive combinations of receptors and odorants. Finally, the apparent diversity of the receptor sequences should further enhance the scan of the odor space. The above-described experiments screened 80 clones (not counting the I7 receptor) against 26 odorants. Because a given odorant should be recognized by at least one member of, say, a total of 1000 receptors, the chance of encountering an odorant that is a cognate ligand to 80 receptors should, on average, be 8% (= 80/1000), or 2 positives in a pool of 26 odorants. This number is close to the number (3) identified experimentally herein. The receptor library generated with a single pair of degenerate primers of the invention (the TM II to TM VII amplifying pair) encompasses a broad range of the olfactory receptor family. Several hundred distinct sequences are represented in this exemplary library of the invention.

The addition of translocation domains of the invention (the first twenty amino-acid residues of a rhodopsin N-terminal segment, with some exemplary domains also consisting of a 5'-untranslated rhodopsin region) to the chimeric olfactory receptors of the

invention facilitated their plasma membrane localization. This included the full-length I-C6 receptor, where the inclusion of the translocation domain was necessary in order to observe a response to (-) citronellal. The different translocation domains of the invention may be aiding in the translocation process in different ways; however, the invention is not limited by what structural contribution may be played by the translocation domain to the newly translated protein's translocation process.

5

**What is claimed is:**

1. An amplification primer sequence pair for amplifying a nucleic acid encoding an olfactory receptor ligand-binding region comprising a first primer comprising a sequence 5'-GGGGTCCGGAG(A/G)(C/G)

5 (A/G)TA(A/G/T)AT(A/G/P)A(A/G/P)(A/G/P)GG-3' (SEQ ID NO:1) and a second primer comprising a sequence 5'-GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T) (C/T)T(A/C/G/T)TT(C/T)(C/T)T-3' (SEQ ID NO:2).

10 2. The amplification primer sequence pair of claim 1, wherein the receptor ligand-binding region comprises olfactory receptor transmembrane domains II through VII.

3. A method for generating nucleic acid sequence that encodes a ligand-binding region of an olfactory receptor, the method comprising amplification of a nucleic acid using a primer pair as set forth in claim 1.

15 4. The method of claim 3, wherein the amplified nucleic acid is genomic DNA, mRNA or cDNA derived from olfactory neurons or olfactory epithelium.

20 5. The method of claim 3, wherein the amplification comprises the following conditions and steps in the following order:

about one cycle at about 94°C for about 2 min; and

about 30 cycles of about 45°C to about 65°C for about 1 min, followed by about 72°C for about one min. followed by about 94°C for about 1 min.

25 6. The method of claim 5, wherein the PCR amplification further comprises the following conditions and steps in the following order:

about one cycle of about 45°C to about 65°C for about 10 min; and

about one cycle of about 72°C for about 10 min.

30 7. A kit for amplification of olfactory receptor sequences comprising the primer pair of claim 1.



8. A library of olfactory receptor ligand-binding regions consisting essentially of olfactory receptor transmembrane domain regions II through VII, II through VI, III through VII, or III through VI.

5 9. The library of claim 8, wherein the olfactory receptor ligand-binding regions are generated by polymerase chain reaction using degenerate primer pairs.

10. A library of chimeric nucleic acid sequences comprising the following domains in 5' to 3' order:

10 a nucleic acid encoding an amino terminal plasma membrane translocation domain;

a nucleic acid encoding a first transmembrane domain; and

a nucleic acid encoding an olfactory receptor ligand-binding region,

15 wherein the chimeric nucleic acid sequence encodes a 7-transmembrane polypeptide that can transverse a plasma membrane seven times.

11. The library of claim 10, wherein the amino terminal plasma membrane translocation domain comprises a sequence as set forth in SEQ ID NO:3.

20 12. The library of claim 10, wherein the first transmembrane receptor is a 7-transmembrane receptor region I domain.

25 13. The library of claim 12, wherein the 7-transmembrane receptor transmembrane region I domain comprises a sequence as set forth in SEQ ID NO:4.

14. The library of claim 10, wherein the olfactory receptor ligand-binding region comprises olfactory receptor transmembrane domain regions II through VII, II through VI, III through VII, or III through VI.

30 15. The library of claim 10, wherein the olfactory receptor ligand-binding regions are generated by polymerase chain reaction using degenerate primer pairs.

16. The library of claim 14, wherein the nucleic acid sequence encoding the transmembrane domain regions II through VII is generated by polymerase chain reaction (PCR) amplification of nucleic acid using a first primer comprising a sequence 5'-GGGGTCCGGAG(A/G)(C/G)(A/G)TA(A/G/T)AT(A/G/P)A(A/G/P)(A/G/P)GG-3' (SEQ ID NO:1) and a second primer comprising a sequence 5'-GGGGCTGCA GACACC(A/C/G/T)ATGTA(C/T)(C/T)T(A/C/G/T)TT(C/T)(C/T)T-3' (SEQ ID NO:2).

17. The library of claim 15, wherein the PCR-amplified nucleic acid is genomic DNA, mRNA or cDNA derived from olfactory neurons or olfactory epithelium.

18. The library of claim 10, wherein the ligand-binding region comprising transmembrane domains II through VII is an amino acid sequence encoded by a nucleic acid selected from the group consisting of SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:19, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:41, SEQ ID NO:43, SEQ ID NO:45 and SEQ ID NO:47, or an amino acid sequence selected from the group consisting of SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:44, SEQ ID NO:46, SEQ ID NO:48.

19. The library of claim 15, wherein the PCR amplification comprises the following conditions and steps in the following order:

about one cycle at about 94°C for about 2 min;  
about 30 cycles of about 55°C for about 1 min, followed by about 72°C for about one min. followed by about 94°C for about 1 min;  
about one cycle of about 55°C for about 10 min; and  
about one cycle of about 72°C for about 10 min.

20. The library of claim 10, further comprising a carboxy terminal 7-transmembrane receptor transmembrane region VII domain.

21. The library of claim 20, wherein the 7-transmembrane receptor transmembrane region VII domain comprises a sequence as set forth in SEQ ID NO:5.

22. A library of nucleic acid sequences comprising the following domains in 5' to 3' order

a nucleic acid encoding an amino terminal plasma membrane translocation domain comprising a sequence as set forth in SEQ ID NO:3,

a nucleic acid encoding a transmembrane region I domain comprising a sequence as set forth in SEQ ID NO:4,

a nucleic acid sequence generated by polymerase chain reaction (PCR) amplification of mRNA or cDNA derived from olfactory epithelium using a first primer comprising a sequence 5'-GGGGTCCGGAG(A/G)(C/G)T(A/G)A(A/G/T)AT(A/G/P)A(A/G/P)(A/G/P)GG-3' (SEQ ID NO:1) and a second primer comprising a sequence 5'-GGGGCTGCAGACACC(A/C/G/T)ATGTA(C/T)C/T)T(A/C/G/T)TT(C/T)C/T)T-3' (SEQ ID NO:2), and

a nucleic acid encoding a 7-transmembrane receptor transmembrane region VII domain comprising a sequence as set forth in SEQ ID NO:5.

23. An expression vector comprising a nucleic acid sequence derived from a library of nucleic acid sequences as set forth in claim 8 or claim 10.

24. A transformed or isolated infected cell comprising a nucleic acid sequence derived from a library of nucleic acid sequences as set forth in claim 8 or claim 10 or an expression vector as set forth in claim 23.

25. A transgenic animal comprising a nucleic acid sequence derived from a library of nucleic acid sequences as set forth in claim 8 or claim 10 or an expression vector as set forth in claim 23.

26. The transgenic animal of claim 22, wherein the expression vector is a mammalian expression vector that can be expressed in olfactory epithelium or olfactory neurons.

27. A library of recombinant polypeptides translated or derived from the library of nucleic acids as set forth in claim 8 or claim 10.

5 28. An isolated polypeptide isolated or derived from the library of polypeptides as set forth in claim 27.

29. A method of determining whether a test compound specifically binds to a mammalian olfactory receptor comprising the following steps:

10 (i) expressing a nucleic acid derived from a nucleic acid library as set forth in claim 8 or claim 10 under conditions permissive for translation of the nucleic acid to a receptor polypeptide;

(ii) contacting the translated polypeptide with the test compound; and

15 (iii) determining whether the test compound specifically binds to the polypeptide.

30. A method of determining whether a test compound specifically binds to a mammalian olfactory transmembrane receptor comprising the following steps:

20 (i) contacting a cell stably or transiently transfected with a nucleic acid derived from a nucleic acid library as set forth in claim 8 or claim 10;

(ii) culturing the cell under conditions permissive for translation of the nucleic acid to a receptor polypeptide with the test compound; and

25 (iii) determining whether the test compound specifically binds to the receptor polypeptide.

31. The method of claim 30, wherein the receptor polypeptide is expressed as a transmembrane receptor with a ligand binding site on the cell's plasma membrane outer surface.

30 32. The method of claim 30, wherein the specific binding of the test compound to the polypeptide is determined by measuring a change in the physiologic activity of the cell, wherein a change in the cell's activity measured in the presence of the test compound

compared to the cell's activity in the absence of the test compound provides a determination that the test compound specifically binds to the polypeptide.

33. The method of claim 32, wherein the measured cell activity is a change in the calcium ion ( $\text{Ca}^{2+}$ ) or cAMP concentration in the cell.

34. The method of claim 33, wherein the calcium ion concentration is measured by loading the cell with a calcium ion-sensitive fluorescent dye before contacting the cell with the test compound.

35. The method of claim 30, wherein the cell is a human cell or a *Xenopus* oocyte.

36. A method of determining whether a test compound specifically binds to a mammalian olfactory transmembrane receptor polypeptide *in vivo* comprising the following steps:

(i) contacting a non-human animal stably or transiently infected with a nucleic acid derived from the library as set forth in claim 8 or claim 10 or an expression vector as set forth in claim 23 with the test compound; and

(ii) determining whether the animal reacts to the test compound by specifically binding to the receptor polypeptide, wherein the specific binding of the test compound to the polypeptide is determined by measuring a change in a physiologic activity of the animal, wherein a change in a receptor-encoding vector-infected animal's activity measured in the presence of the test compound compared to a bare vector-infected animal's activity in the presence of the test compound provides a determination that the test compound specifically binds to the mammalian olfactory transmembrane receptor polypeptide.

37. The method of claim 36, wherein the measured physiologic activity is measured by an electroolfactogram.

38. The method of claim 36, wherein the vector is an adenovirus expression vector.

39. A method of determining whether a test compound is neurotoxic to an olfactory neuron expressing an olfactory transmembrane receptor polypeptide comprising the following steps:

(i) contacting an olfactory neuron cell stably or transiently infected with a nucleic acid derived from a library as set forth in claim 8 or claim 10 or an expression vector as set forth in claim 23 with the test compound; and

(ii) measuring the physiologic activity of the cell, wherein a change in the cell's activity measured in the presence of the test compound compared to the cell's activity in the absence of the test compound provides a determination that the test compound is toxic.

40. The method of claim 39, wherein toxicity is indicated by abnormal calcium ion, cAMP or plasma membrane homeostasis.

41. A peptide domain for the efficient translocation of a newly translated protein to a plasma membrane comprising an amino acid sequence as set forth in SEQ ID NO:3 or an amino acid sequence having conservative amino acid residue substitutions based on SEQ ID NO:3.

42. The peptide translocation domain of claim 41, wherein the translocation domain is about 20 amino acids in length.

43. The peptide translocation domain of claim 41, wherein the polypeptide translocation domain is SEQ ID NO:3.

44. The peptide translocation domain of claim 41, wherein the newly translated protein is a transmembrane protein.

45. The peptide translocation domain of claim 41, wherein the transmembrane protein is a 7-transmembrane protein receptor.

46. The peptide translocation domain of claim 45, wherein the 7-transmembrane protein receptor is an olfactory receptor.

47. A hybrid polypeptide comprising an amino terminal amino acid sequence comprising a peptide translocation domain as set forth in claim 41 and a second polypeptide sequence, wherein the second polypeptide sequence is not a rhodopsin polypeptide sequence.

5

48. The hybrid polypeptide of claim 47, wherein the second polypeptide sequence is a transmembrane protein.

10

49. The hybrid polypeptide of claim 48, wherein the transmembrane protein is a 7-transmembrane protein receptor.

50. The hybrid polypeptide of claim 49, wherein the 7-transmembrane protein receptor is an olfactory receptor.

15

51. An isolated or recombinant nucleic acid sequence encoding the hybrid polypeptide of claim 47.

1/2




FIG. 1A



2/2




FIG. 1B

SUBSTITUTE SHEET (RULE 26)

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/30221**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : Please See Extra Sheet.

US CL : 435/7.1, 7.21, 320.1, 325; 530/350; 536/23.5; 800/3, 13

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/7.1, 7.21, 320.1, 325; 530/350; 536/23.5; 800/3, 13

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EAST, BIOSIS, EMBASE, MEDLINE, DERWENT BIOTECHNOLOGY, CAS

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
Y	SINGER et al. Potential Ligand-Binding Residues in Rat Olfactory Receptors Identified by Correlated Mutation Analysis. Receptors and Channels. 1995, Vol. 3, pages 89-95, see the entire document.	8-10, 12, 14, 15 17, 19, 20, 23-40
Y	PELOSI, P. Odorant-Binding Proteins. Critical Reviews in Biochemistry and Molecular Biology. 1994, Vol. 29, No. 3, pages 199-228, see the entire document.	8-10, 12, 14, 15 17, 19, 20, 23-40
Y	PARMENTIER et al. La famille des recepteurs couples aux proteines G et ses orphelins. Medecine/Sciences. 1995, Vol. 11, pages 222-231, see the entire document.	8-10, 12, 14, 15 17, 19, 20, 23-40

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

20 APRIL 2000

Date of mailing of the international search report

23 MAY 2000

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BRUCE CAMPELL

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/30221

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim
Y	SINGER et al. Molecular modeling of ligand-receptor interactions in the OR5 olfactory receptor. <i>NeuroReport</i> . 02 June 1994, Vol. 5, No. 10, pages 1297-1300, see the entire document.	8-10, 12, 14, 15 17, 19, 20, 23-4
X, P	KRAUTWURST et al. Identification of Ligands for Olfactory Receptors by Functional Expression of a Receptor Library. <i>Cell</i> . 23 December 1998, Vol. 95, pages 917-926, see the entire document.	8-10, 12, 14, 15 17, 19, 20, 23-4
Y	KIEFER et al. Expression of an Olfactory Receptor in <i>Escherichia coli</i> : Purification, Reconstitution, and Ligand Binding. <i>Biochemistry</i> . 1996, Vol. 35, No. 50, pages 16077-16084, see the entire document.	8-10, 12, 14, 15 17, 19, 20, 23-4
Y	BUCK, L. Identification and Analysis of a multigene family encoding odorant receptors: implications for mechanisms underlying olfactory information processing. <i>Chemical Senses</i> . 1993, Vol. 18, No. 2, pages 203-208, see the entire document.	8-10, 12, 14, 15 17, 19, 20, 23-4
Y	LANCET et al. Olfaction: from signal transduction and termination to human genome mapping. <i>Chemical Senses</i> . 1993, Vol. 18, No. 2, pages 217-225, see the entire document.	8-10, 12, 14, 15 17, 19, 20, 23-4
Y	PARMENTIER et al. Expression of members of the putative olfactory receptor gene family in mammalian germ cells. <i>Nature</i> . 30 January 1992, Vol. 355, pages 453-455, see the entire document.	8-10, 12, 14, 15 17, 19, 20, 23-4

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/30221

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☒ Claims Nos.: 1-7, 11, 13, 16, 18, 21, 22 and 41-51  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
  
Applicant did not provide a sequence listing.
  
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
  
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.  
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/30221

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (7):

A01K 67/00; C07H 21/04; C07K 1/00; C12N 5/00, 15/00; G01N 33/00, 33/53, 33/567

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**